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ABSTRACT 
 
    Campylobacter is a major foodborne pathogen causing human enteric infections. 
Antibiotic treatments are needed for prolonged and severe cases of campylobacteriosis, but 
Campylobacter is increasingly resistant to antimicrobials, which has rendered antimicrobial 
therapy less effective. Multiple mechanisms contribute to antibiotic resistance in 
Campylobacter, but antibiotic efflux mediated by membrane transporters is considered a 
significant player in conferring intrinsic and acquired resistance to a broad spectrum of 
antimicrobials. The recently published genomic sequence revealed the presence of multiple 
genes encoding efflux transporters in C. jejuni, and work conducted in our laboratory 
identified that CmeABC, a RND (resistance nodulation and cell division) type efflux pump, 
serves as a major efflux pump in C. jejuni, contributing to antibiotic resistance, bile 
resistance, and in vivo colonization of the chicken intestinal tract. Work from our laboratory 
also found that that CmeABC is controlled by a transcriptional regulator named CmeR and 
this regulator appears to modulate the expression of multiple membrane transporters in C. 
jejuni. Despite these recent advances, it is unclear if CmeABC is present and functional in 
other Campylobacter spp; the functions and regulatory mechanisms of other efflux 
transporters are not known; and the role of the CmeR-regulated membrane transporters in 
Campylobacter pathophysiology remains to be determined.  In this project, we conducted a 
series of studies to address these questions using both in vitro and in vivo approaches. In the 
first study, we successfully identified CmeABC in C. coli, C. upsaliensis, C. lari, and C. 
fetus and found that the genomic organizations and predicted structures CmeABC are 
conserved in the Campylobacter spp. Insertional mutagenesis of CmeABC showed that this 
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efflux pump is functional in Campylobacter spp. and contributes to their intrinsic resistance 
to a range of structurally diverse antimicrobials and toxic compounds. In the second study, 
we found that Cj0035c (a putative major facilitator superfamily transporter) and Cj0561c (a 
periplasmic fusion protein) are directly regulated by CmeR. Specifically, CmeR binds to the 
promoter regions of Cj0035c and Cj0561c and represses their transcription. Bile salts, which 
are normally present in animal gut, induce the expression of both genes, suggesting that they 
may be upregulated during in vivo infection. Insertional mutagenesis and induction revealed 
that Cj0561c plays a moderate role in antimicrobial resistance in C. jejuni, but a role of 
Cj0035c in antimicrobial resistance was not detected. In addition, the Cj0561c mutant was 
outcompeted by the wild-type strain when co-inoculated into chickens, indicating that 
Cj0561c contributes to Campylobacter adaptation in the intestinal environment. In the third 
study, we investigated the regulation and function of DcuA and DcuB, which are homologs 
of C4-dicarboxylate transporters identified in other bacterial species.  It was demonstrated 
that the expression of dcuA and dcuB in C. jejuni was suppressed by CmeR and both genes 
were inducible by low-oxygen conditions or fumurate. Insertional mutagenesis of the two 
genes indicated that dcuA and dcuB collectively contribute to C. jejuni colonization in 
chicken ceca. The coordinated regulation of the drug efflux transporters and C4-
dicarboxylate transporters by CmeR suggests that the interplay between the two systems has 
an important physiological function in facilitating Campylobacter adaptation to various 
environments. Together, these findings have significantly improved our understanding of the 
efflux transporters in Campylobacter. Targeting the efflux transporters may not only control 
antibiotic resistance, but also potentially prevent Campylobacter colonization in the intestinal 
tract.  
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CHAPTER 1. GENERAL INTRODUCTION 
 
Introduction 
 
    Campylobacter has been recognized as a foodborne human pathogen since the 1970’s. C. 
jejuni and C. coli account for approximately 90% and 10% cases of human 
campylobacteriosis, respectively. This disease is characterized by watery or inflammatory 
diarrhea and abdominal pains. Campylobacter infections in humans may also be 
accompanied by a degenerative neurological disorder named Guillain-Barré syndrome. 
Fluoroquinolone and macrolide antibiotics have been effective in the treatment of 
Campylobacter infections. However, the development of antibiotic resistance in 
Campylobacter has resulted in treatment failure and become a significant public health 
concern. Understanding the mechanisms of antibiotic resistance and bacterial adaptive 
responses will facilitate the development of new intervention strategies that may be used to 
control Campylobacter-associated foodborne diseases.   
 
    Bacterial multidrug efflux pumps are membrane transporters responsible for both intrinsic 
and acquired antibiotic resistance through the extrusion of antibiotics and toxic chemicals 
from bacterial cells. According to sequence and structural homology, bacterial efflux 
transporters are classified into five superfamilies: ATP binding cassette (ABC), resistance 
nodulation and cell division (RND), multidrug and toxic compound extrusion (MATE), 
major facilitator superfamily (MFS) and small drud resistance (SMR). C. jejuni 11168 
harbors 13 putative drug efflux pumps, including one ABC (Cj1187c), two RND (CmeABC 
and CmeDEF), two MATE (Cj0560 and Cj0619), four MFS (Cj0035c, Cj1257C, Cj1375, 
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and Cj1687), and four SMR (Cj0309c, Cj0310c, Cj1173, and Cj1174) transporters. At 
present, CmeABC is the best characterized antibiotic efflux transporter in Campylobacter. 
CmeABC consists of three members including an outer membrane protein (CmeC), an inner 
membrane drug transporter (CmeB), and a periplasmic fusion protein (CmeA).  Studies 
conducted in our laboratory revealed that i) CmeABC confers intrinsic and acquired 
resistance to antimicrobials, contributes significantly to the emergence of fluoroquinolone-
resistant mutants, and is essential for Campylobacter colonization in the intestinal tract by 
mediating bile resistance; ii) expression of cmeABC  is subject to repression by CmeR, a 
transcriptional factor of the TetR family, which binds specifically to the inverted repeat in the 
promoter region of cmeABC; and iii) bile salts, normally present in animal intestinal tract, 
induce the expression of cmeABC by interfering with the binding of CmeR to the operator 
DNA of cmeABC. In addition, our recent results strongly suggest that CmeR functions as a 
global regulator and modulates the expression of multiple genes of diverse functions in 
Campylobacter. Particularly, our preliminary results suggest that CmeR also modulates the 
expression of the MFS and MATE transporters as well as the C4-dicarboxylate transporters 
potentially involved in Campylobacter adaptation to oxygen-limited environments, which 
exist in the intestinal tract of animal hosts. These findings clearly suggest that the regulated 
expression of the antibiotic efflux system may play an important role in antimicrobial 
resistance and in facilitating Campylobacter adaptation to environmental changes. Despite 
the recent advances, the distribution and function of CmeABC in other Campylobacter spp. 
are unknown, the majority of the CmeR-regulated efflux transporters in Campylobacter have 
not been functionally characterized, and the detailed molecular mechanisms governing the 
expression and function of the transporters are not well understood. 
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    To close these important gaps in our understanding of the antibiotic efflux system in 
Campylobacter, we performed in vitro and in vivo experiments to investigate the functions 
and regulatory mechanisms of several CmeR-regulated membrane transporters. Specifically, 
we determined the distribution and function of CmeABC in non-jejuni Campylobacter spp. 
and investigated the regulatory mechanisms and functions of Cj0035c, Cj0561c, DcuA, and 
DcuB in antibiotic resistance and Campylobacter adaptation in the intestinal tract of 
chickens.  
 
Dissertation Organization 
 
    Proceeded by an abstract, this dissertation is organized by the alternative format with 5 
chapters. Chapter 1 contains a general introduction. Chapter 2 contains a literature review. 
Chapter 3 through 5 each contains a manuscript to be submitted to the ASM journals. 
Chapter 6 is the general conclusion. At the end of each chapter are appended references cited 
followed by tables and figures. 
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CHAPTER 2. A REVIEW OF CAMPYLOBACTER INFECTIONS, VIRULENCE, 
ANTIBIOTIC RESISTANCE, ADAPTATION AND PREVENTION 
 
Introduction 
 
    The genus of Campylobacter, which is under the Campylobacteracae Family, currently 
includes 17 members: C. coli, C. concisus, C. curvus, C. fetus, C. gracilis, C. helveticus, C. 
hominis, C. hyointestinalis, C. insulaenigrae, C. jejuni, C. lanienae, C. lari, C. mucosalis, C. 
rectus, C. showae, C. sputorum and C. upsaliensis. Although most of the Campylobacter spp. 
have been associated with veterinary and human infections, C. jejuni and C. coli are the most 
common Campylobacter spp. that cause foodborne illnesses in humans.  C. fetus has been 
implicated in cattle and sheep abortions and opportunistic infections in humans. Since C. 
jejuni was recognized as a human pathogen in the 1970’s, Campylobacter infections have 
become a major foodborne disease worldwide, accounting for one fourth of the bacterial 
enteric infections. Although outbreaks of Campylobacter infections are rare, sporadic cases 
are common in the United States and other developed countries. Complications from 
Campylobacter infections can cause severe and life-threatening diseases, such as Guillain-
Barré syndrome. Due to the self-limiting nature of Campylobacter infections, antibiotic 
treatment is usually not needed. But antibiotic therapy is necessary in severe cases such as 
infections occurring in elderly and immunocompromised patients. Macrolide and 
fluoroquinolones have been successfully used in the treatments of Campylobacter infections. 
However, due to the frequent clinical use of antibiotics for human diseases and the licensed 
use of antibiotics in food producing animals, bacterial resistance to fluoroquinolone and 
macrolides has been increasing since the early 1990’s. Most of Campylobacter infections 
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have been caused by the consumption of contaminated meat, milk and water. Poultry and 
farm animals have been implicated as the major sources of human infections. At present, no 
effective interventions are available in controlling the development and persistence of 
antibiotic resistance in Campylobacter. No vaccines are currently available to prevent 
Campylobacter colonization in animals and humans. The mechanisms of antibiotic resistance 
in Campylobacter have been well elucidated in the recent years. Specifically, point mutations 
of gyrA and 23S ribosomal RNA genes along with the major multidrug resistance efflux 
pump are major determinants for resistance to fluoroquinolones and macrolides. Significant 
advances have been achieved in understanding the physiology, pathogenesis, and virulence 
mechanisms of Campylobacter. This review will provide an updated summary of 
Campylobacter infections, virulence, physiology, adaptation, and resistance to antimicrobials 
as well as control measures.  
 
Campylobacter Infections 
 
General characteristics of C. jejuni 
 
    C. jejuni is a spiral, S-shaped Gram-negative rod with single or bipolar flagella, with 
corkscrew motility. Campylobacter has a typical Gram-negative bacterial cell wall structure, 
with the outer membrane composed of lipopolysaccharide, outer membrane proteins, 
lipoproteins and polysaccharide (102). The C. jejuni NCTC 11168 has a genome of 1.64 Mb 
with a low G+C content of 30.6%, encoding 1654 open reading frames (ORFs) (95). 
Although the requirement for low O2 gas for in vitro growth may vary among the 
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Campylobacter spp., most require the presence of low O2 (3 to 15%) and CO2 (2% to 10%) 
for optimal growth.  Most Campylobacter spp. can grow at 37 °C. Thermophilic 
Campylobacter spp., such as C. jejuni, C. coli, and C. lari, grow optimally at 42 °C. Isolation 
of C. jejuni and C. coli is performed at either 42 °C or 37 °C under an atmosphere of 5% O2, 
10% CO2 and 85% N2. Campylobacter cannot utilize glucose and other hexoses as carbon 
sources due to the lack of phosphofructosekinase which is a checkpoint in glycolysis. Amino 
acids are usually used as an energy sources for growth. Therefore, nutrient-rich media, such 
as Brucella broth, Mueller-Hinton broth and etc., have been used for culturing 
Campylobacter. Culture of certain Campylobacter strains may require whole blood from 
horse or sheep, or iron supplement to be added in the culture medium.   
    
Infections in humans and animals 
 
    C. jejuni and C. coli are the major species causing foodborne illnesses, which account for 
85%-95% and 5%-15% of human campylobacteriosis, respectively (87). C. upsaliensis and 
C. concisus have been frequently isolated by filtration onto antibiotic-free media from 
diarrheic patients in South Africa and incubation at 37 °C, but the clinical significance of 
these Campylobacter spp. in humans remains unknown (65, 86).  
 
    Gastroenteritis is the main clinical symptom of Campylobacter infections in humans, 
which is characterized by abdominal pains, fever, and diarrhea. The infectious dosage for 
human can be as low as 500 bacterial cells (124). Campylobacter-associated enteritis in 
humans usually undergoes an acute phase after an average incubation period of 3 days. The 
diarrhea can last up to 1 or 2 weeks and often can be self-limiting without the need for 
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treatment (124). Patients can shed Campylobacter after the diarrhea stage for up to 38 days 
without antibiotic treatment, but human to human transmission rarely occurrs in developed 
countries (124). Severe disease and prolonged bacterial carriage has been observed in 
immune deficient patients (124). In addition to the gastrointestinal tract, Campylobacter also 
can cause diseases in other organs or systems, such as bacteremia, hepatitis, cholecystitis, 
myocarditis, nephritis, and abortion (23). Campylobacter can also cause severe and long term 
clinical complications, such as Guillain-Barré syndrome (GBS) (124).  
 
    In animals, C. jejuni and C. coli usually do not produce clinical diseases. It has been 
reported that C. jejuni, C. upsaliensis and C. lari can cause diarrhea in pets, but the bacteria 
can also be isolated from healthy animals. C. jejuni and C. fetus have been reported to cause 
abortions and infertility in cattle and sheep. In addition, C. fetus subspp. fetus has also been 
known as an opportunistic pathogen in humans, causing septicemia.  
  
Epidemiology and Transmission 
 
    Domestic poultry are regarded as one of the major sources of human Campylobacter 
infections (128). C. jejuni has been frequently isolated from raw chicken meat sold in grocery 
stores. Broilers, layers and turkeys have high rates of carriage for C. jejuni on farms. The 
correlation between the consumption of chicken meat and Campylobacter infections in 
humans has been demonstrated in several studies (29, 44, 116, 123). Genotypic analysis of 
chicken isolates from patients and raw meat from local grocery store indicates contaminated 
meat was the major sources of Campylobacter infections (40, 115). In another investigation 
in Belgium in 2001 when chicken meat was withdrawn from supermarkets because of the 
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dioxin contamination of feed products, Campylobacter infections in humans decreased by 
40%, which was an indication that the consumption of poultry meat is a major risk factor for 
Campylobacter infection (143). C. coli mainly inhabits the intestines of swine and turkey. 
The genotypes of C. coli from a variety of sources have been investigated and only C. coli of 
poultry origins were correlated with human diseases (39, 50, 161). Pigs have been known as 
carriers of C. coli, but the frequency of pork meat contamination by Campylobacter are much 
lower than those on chicken meat (32, 78, 157). Other causes of human Campylobacter 
infections may be the consumption of unpasteurized milk and unchlorinated surface water, 
inappropriate handling of raw meat from carrier animals and frequent contacts with infected 
and sick animals (15, 56, 122). Isolation of Campylobacter from pets has been reported (5) 
and pets infected by Campylobacter can transmit the disease to the host family members 
(21). 
 
    On poultry farms, broilers and turkey usually become colonized by C. jejuni two and three 
weeks after hatching, respectively, presumably via horizontal transmission from the 
surrounding environment. It was demonstrated that even in a strictly isolated environment, 
birds could become C. jejuni carriers in a couple of weeks, which coincides with the decrease 
of the maternal antibodies in the chickens (120). Many studies have been conducted to 
identify the sources of infections for young birds on farms. Horizontal transmission is 
currently regarded as the major route for the rapid dissemination of C. jejuni. Eggs from 
infected birds do not carry viable bacteria and vertical transmission is insignificant, if it 
exists, in the transmission of C. jejuni in chickens (13, 119, 121). It has been speculated that 
C. jejuni can be mechanically carried by human or other inanimate media from unidentified 
sources, contributing to the infections of young birds. It was demonstrated in a recent study 
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that C. jejuni strains could be isolated from the surrounding environment and genotypes of 
the environmental isolates matched the isolates from the birds (8). Chicken farms with good 
biosecurity measures experienced delayed infections by C. jejuni from the environment (49).   
 
    Studies performed on dairy, beef cattle and sheep farms showed that Campylobacter spp., 
mainly C. jejuni and C. coli, can be frequently isolated from animals, although the rates of 
isolation may vary in different herds (27, 45, 46). Livestock infected by Campylobacter are 
often chronic carriers and shedders of Campylobacter and play an important role in the 
dissemination of Campylobacter in the environments through contaminating surface water 
and soil (43). A British study demonstrated that Campylobacter can be isolated from 
environments, such as puddles, equipment, wild animals and sheep, which are potentially the 
sources of initial Campylobacter  infections in broiler flocks (8). Campylobacter spp. have 
also been isolated from migrating birds and other wildlife, which may serve as a source of 
infections in domesticated animals and poultry as well as humans (52, 68). 
 
    The economic impact of Campylobacter is enormous. It has been estimated in a study 
published in 1997 that the losses due to the medical expenses and loss of productivity caused 
by human Campylobacter infections ranged from $1.3 to 6.2 billions annually (10). 
Complications due to Guillain-Barré syndrome can cause additional losses of $0.2 to 1.8 
billion (9). Although a 2004 FoodNet Report indicated that the overall rate of Campylobacter 
infections in the US declined by 33% compared with the rates from 1996 to 1998 (89), the 
economic burden is still significant .  
 
Pathogenesis and Virulence 
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    Studies on Campylobacter pathogenesis and virulence have been hampered by the lack of 
an ideal animal model to evaluate the pathogenesis and virulence of Campylobacter isolated 
from humans. Numerous studies have been done to elucidate the pathogenesis and virulence 
of Campylobacter and the major findings in this area have been mainly derived from studies 
using in vitro cell cultures, animal models, and the observations of clinical cases. Since 
Campylobacter spp. are a group of enteric pathogens, factors which promotes the adhesion 
and invasion to the intestinal cells, intestinal colonization, motility, chemotaxis, and serum 
resistance, etc., have been related to pathogenicity. 
 
    Attachment and invasion of intestinal cells by Campylobacter are the first two steps 
causing intestinal diseases. The bacterial cell components involved in adhesion and invasion 
have been studied extensively using in vitro cell cultures and in vivo model systems.  An 
outer membrane protein (CadF) and an adhesin protein (Peb1a, or CBF1) have been 
experimentally shown to be responsible for Campylobacter adhesion to intestinal cells (57, 
60, 100). CadF and Peb1a can directly interact and bind to the intestinal surface and the 
binding can be blocked by specific antibodies to CadF and Peb1a.  CadF can bind to 
fibronectin in the extracellular matrix of intestinal cells.  Experiments also showed that 
mutations in cadF and peb1a impaired Campylobacter adhesion and invasion (85). The cadF 
mutant cannot colonize the chicken cecum (160) and the peb1a mutant cannot colonize in 
mouse intestines (101). Recently, the fibronectin binding domain of CadF has been identified 
(59). Peb1a was identified as a periplasmic solute binding protein that is part of an ABC 
transporter responsible for the transport of dicarboxylate amino acids. Analysis of chicken 
Campylobacter isolates by PCR indicated that all of the tested isolates have CadF (6, 158). 
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JlpA, a Campylobacter surface lipoprotein, is involved in HEp-2 cell adhesion and the 
interaction with HEp-2 cell heat shock protein leads to the activation of NF-κB and p38 MAP 
kinase (47, 48). The mechanism of Campylobacter invasion into host cells has also been 
extensively studied recently, but the molecular bases for the internalization and the 
translocation of Campylobacter by the intestinal cells is unknown (30). It has been shown 
that the microfilaments (MF) and microtubules (MT) are required for internalization and the 
process is potentially coordinated with cellular changes through signal transduction during 
cell invasion (85). De novo protein synthesis by Campylobacter is essential for cell invasion 
and CiaB (Campylobacter invasion-associated antigen B) is required for the invasion of INT 
107 cells, but not for the adhesion (61). The secretion of Cia depends on the flagellar 
secretion system (62). Another protein, FlaC, which resembles FlaA and FlaB in the N- and 
C- terminal ends, but is a nonflagellar protein, is secreted by the flagellar secretion system 
into the extracellular milieu.  The mutation of FlaC affects Caco-2 cell invasion, but the 
adhesion process was not affected (125). 
 
    Campylobacter has uni- or bipolar flagella that enable the bacterium to move using a cork 
screw style movement, allowing Campylobacter swimming through the viscous mucus 
covering the intestinal epithelia to invade the cells. Flagella in C. jejuni and C. coli have been 
extensively studied. The flagellum is composed of two flagellin monomers,  encoded by flaA 
and flaB (38). The flaA and flaB genes are arranged in tandem in C. jejuni genome, under the 
control of σ28 and σ54 factors, respectively. FlaA and FlaB share amino acid homology of 
91.9%  (38). Mutagenesis and animal studies indicated that FlaA is the major component of 
flagella (149). Although the exact function of each type of flagellin remains unknown, both 
FlaA and FlaB are required for full length flagella expression and motility. Flagella have 
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been suggested to function as a secondary adhesin and the mutants deficient in INT 107 cell 
invasion were nonmotile with abnormal flagella (154). In another study, it was demonstrated 
that Campylobacter had a longer period of straight swimming interspersed with tumbling in a 
high viscous environment, and the adhesion and invasion of Caco-2 cells was significantly 
enhanced by the high viscosity (132). 
 
    Campylobacter lipopolysaccharide (LPS) has been shown to be involved in adhesion to 
INT 107 cells (82). Mutation in galE, which encodes a UDP-galactose 4-epimerase involved 
in the LPS synthesis, significantly affects the mutant cell adhesion and invasion (31). An N-
linked protein general glycosylation (Pgl) pathway was identified in C. jejuni recently and 
mutations of pglH, which resulted in deficiency in the glycosylation of a number of proteins, 
also affected the Caco-2 cell adhesion and invasion significantly (53). Other proteins 
involved in cell adhesion and invasion include a glycoprotein Cj1469 (51) and a periplasmic 
protease HtrA (7).  Animal studies also demonstrated that mutants of pglH, cj1469 and htrA 
had significant reduced ability to colonize the intestinal tract (7, 31, 53). Other proteins or 
factors contributing to the in vivo colonization include RND family efflux pump CmeABC 
(73), iron acquisition related FeoB (88), a putative aminotransferase (Cj1121c) for protein 
glycosylation (145), and the flagellin glycosylation locus responsible for the glycosylation of 
flagella (80). 
 
Immune Responses 
 
    Campylobacter can elicit both mucosal and circulatory antibody responses upon infection 
and the immune responses are protective against reinfection by Campylobacter. Flagella and 
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several other immunodominant antigens have been identified  in Campylobacter (16, 151, 
152).  Maternal antibodies against Campylobacter have been shown to be protective to 
newborn offspring in both humans and animals (117, 120, 133, 135). Campylobacter capsule, 
lipooligosaccharide (LOS)/ lipopolysaccharide (LPS) can also induce antibody responses. 
However, due to the molecular mimicry between Campylobacter LOS/ LPS and GM1 
ganglioside in human neuron tissue, the anti-LOS/LPS antibodies of certain serotypes can 
cross-react with peripheral neuron tissue and cause autoimmune diseases, such as Guillain-
Barré syndrome (155), which represent a major clinical complications post Campylobacter 
infection.  Guillain-Barré syndrome can occur at the rate of 0.1% of the Campylobacter 
infected patients. 
 
    Information on the cellular immune responses has been sketchy. Gastrointestinal lining 
epithelium serves as both a physical barrier and sensor of intestinal infections (159). It was 
demonstrated by using INT 107 cells that viable Campylobacter cells, cell lysate and filtrate 
can stimulate INT 107 cell to secrete INF- γ, TNF-α, IL-4 and IL-10 (3). Peripheral blood 
mononuclear cells (PBMC) from healthy humans negative for Campylobacter IgM and IgA 
but positive for IgG were tested with C. jejuni isolates of different serotypes and it was 
demonstrated that γδ T cells were stimulated (139). In another study using Caco-2 cells, it 
was demonstrated that Campylobacter can induce the production of human β-defensins, 
which may play a significant role in innate immunity against bacterial infection (159).  
 
Physiology and Adaptation 
 
Energy Sources and Metabolic Features 
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    C. jejuni can not use glucose, or other hexose as carbon sources and this was corroborated 
by the genome sequence of C. jejuni 11168 (55, 95), in which the gene for the critical 
enzyme 6-phosphofructokinase in the glycolysis pathway was found to be absent (95). Since 
the enzymes of the gluconeogenesis are identified in C. jejuni genome, however, biosynthesis 
of glucose from phosphoenopyruvate is possible (95).  The functional prediction based on the 
C. jejuni 11168 genome indicated that C. jejuni has a complete citric acid cycle (CAC) that 
can serve for both catabolism and biosynthesis in C. jejuni (55, 95). Critical enzymes 
involved in the replenishment of the CAC include pyruvate carboxylase (encoded by pycA 
and pycB),  phosphoenolpyruvate carboxykinase (encoded by pckA) and malate 
oxidoreductase (encoded by cj1287c) have been experimentally detected in C. jejuni (55, 83).  
Mutagenesis studies indicated that pckA may be essential in C. jejuni, and pycA mutants can 
not grow on defined medium with pyruvate or lactate as carbon sources but can grow well in 
rich medium. The entry of pyruvate into CAC is catalyzed by pyruvate dehydrogenase in 
aerobic condtions and pyruvate:acceptor oxidoreductase (55). The oxidoreductase gene has 
been identified in the C. jejuni 11168 genome (55, 95) and this enzyme has been shown to be 
sensitive to oxygen in Helicobacter pylori (55).   
 
    Since C. jejuni cannot utilize hexose, amino acids are the major carbon and energy 
sources. Enzymes have been predicted from C. jejuni 11168 genome that enable C. jejuni to 
utilize aspartate, asparagine, glutamate, glutamine, serine, and proline (55). In an earlier 
study, it was demonstrated that C. jejuni had a high preference for serine and aspartate versus 
low preference to glutamate, proline and other amino acids (66). Recently, SdaA was 
identified in C. jejuni as a serine dehydratase and is thought to play an important role in in 
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vivo colonization by C. jejuni, although the sdaA mutants can grow normally in rich medium 
in vitro (142).  
 
Adaptations in Natural Environments and Hosts 
 
    The optimal growth temperature for C. jejuni is 42°C in vitro. But Campylobacter has also 
been shown to grow between 30°C to 36°C (41). The cold shock proteins, which have been 
identified in other bacteria, have not been identified in Campylobacter. This may explain 
why the shift to low temperature causes cessation in growth (41). However, the bacterium is 
still motile and metabolically active at 4°C as shown by oxygen respiration, catalase activity, 
ATP and protein synthesis (41). C. jejuni kept at 4°C maintained the spiral shape longer than 
C. jejuni incubated at 37°C, which soon changed to coccoid form with obvious DNA 
degradation (42). Another study demonstrated that the sustained viabilities of different strains 
at  4°C are variable and human clinical isolates maintained a significantly longer life than 
poultry isolates at low temperature (17). But the sensitivity to frozen and freeze-thawing 
conditions are variable among C. jejuni strains regardless of the sources of isolates (17).  
 
    Most Campylobacter can only grow under microaerobic conditions due to the generation 
of reactive oxygen intermediates (ROIs) in metabolism under high oxygen conditions (94).  
ROIs are toxic to living cells due to the damage they cause to DNA, proteins and lipids. 
Catalase (KatA), superoxide dismutase (SOD), alkyl hydroperoxide reductase (AhpC) and 
ferredoxin protein (FdxA) have been identified in Campylobacter and are involved in 
aerotolerance and resistance to oxidative stresses (37, 113, 140, 144). KatA of C. jejuni plays 
an important role in aerotolerance and intracellular survival in macrophages (22). SOD is 
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important for Campylobacter intracellular survival and in vivo colonization (105, 112) and 
also plays a role in the survival of Campylobacter in the process of freeze-thawing during 
which superoxide is produced (126). AhpC is iron-regulated and important in the resistance 
to aerotolerance and oxidative stress (4). FdxA, encoded by a gene adjacent to ahpC in C. 
jejuni, mediates aerotolerance, but mutations in FdxA did not reduced the oxidative stress 
resistance of the mutant  (140). The regulation of oxidative stress resistance in E. coli is 
through SoxS-SoxR and OxyR, which serve as repressors and are inducible by oxidative 
stress conditions. In C. jejuni, both SoxS-SoxR and OxyR were not identified in the 
sequenced genome. PerP is involved in the oxidative stress resistance regulation in Bacillus 
subtilis, and a PerP homolog has been identified in C. jejuni (141). PerP in C. jejuni serves as 
a repressor of katA and ahpC, but these two genes are also subject to Fur regulation and 
potentially are regulated by an unidentified mechanism (141). 
 
Mechanisms and Prevalence of Antibiotic Resistance 
 
Antibiotic Resistance Due to Target Mutations 
 
    Fluoroquinonlone and macrolide antibiotics have been the choices for the treatment of 
human Campylobacter infections. They both have been licensed for therapeutic purposes in 
food production animals, and macrolides have been used for growth promotion as well. 
Fluoroquinolones inhibit DNA replication by acting on DNA topoisomease II (DNA gyrase) 
and topoisomerase IV. DNA gyrase catalyses the supercoiling process of DNA, which is an 
essential step in DNA synthesis and transcription. Fluoroquinolones bind to DNA gyrase and 
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interfere with DNA replication by causing the DNA gyrase to be trapped on DNA.  
Macrolide antibiotics interfere with protein synthesis through binding to the 50S ribosome 
subunit, cause the dissociation of peptidyl-tRNA in the elongation cycle.  
 
    Target mutations are the major mechanisms by which bacteria develop resistance to 
fluoroquinolone and macrolide antibiotics. DNA gyrase is composed of gyrase A and B 
subunits. A point mutation at Thr-86 of gyrA results in high levels of resistance to 
fluoroquinolones. Other point mutations in gyrA have also been found, resulting in the 
changes Asp-90 and Ala-70, but the resistance level of these mutants is low compared with 
the Thr-86 mutation. The resistance to macrolide antibiotics is mediated by several 
mechanisms in bacteria: target modification, target mutation, inactivation of antibiotics and 
multidrug efflux pumps (35).The major mechanism of resistance to macrolide antibiotics in 
C. jejuni and C. coli is through the point mutation in the 23S rRNA gene. Specificially the 
A2075G mutation in two or more copies of the 23S rRNA gene is responsible for high level 
resistance to macrolide antibiotics (35, 79). The A2074G mutation was also shown to confer 
high levels of macrolide resistance in C. jejuni, but this mutation is less stable than A2075G 
(99). An A2074C transversion mutation in 23S rRNA occurs infrequently and is associated 
with low level of macrolide resistance in C. jejuni strains (35).  Mutation of G74D in the L4 
protein and insertion at amino acid 86 or 98 in the L22 protein can also result in low levels of 
macrolide resistance in C. jejuni (11).  Target methylation and inactivation of antibiotics 
have not been identified in C. jejuni and C. coli (35). Mutations in 23S rRNA (A2075G) or 
ribosomal proteins (L4 and L22) appear to function synergistically with the CmeABC efflux 
pump in the resistance to macrolides in C. jejuni  (11, 12).    
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Campylobacter Efflux Transporters and Regulation 
 
    Efflux transporters are associated with the multidrug resistance (MDR) phenotypes in 
many bacterial species. Efflux transporters are transmembrane proteins that exist in both 
eukaryotic and prokaryotic cells and are responsible for the extrusion of antibiotics and toxic 
compounds out of the cells. Many kinds of efflux transporters have been identified and they 
are classified according to the sequence homologies, three dimensional structures, and energy 
sources.  The major efflux transporters in prokaryotic cells fall into the following 
superfamilies: RND (resistance, nodulation and cell division family), MFS (major facilitator 
superfamily), ABC (ATP-binding cassette superfamily), SMR (small multidrug resistance) 
and MATE (multidrug and toxic compound extrusion) (108). Experimental studies and 
genomic sequence analysis indicated that efflux transporters are ubiquitous and some 
bacteria, such as Pseudomonas aureginosa and E. coli, have multiple efflux transporter 
systems (97). Bacterial efflux transporters are usually encoded on chromosome, but can also 
be encoded on plasmids. Bacterial efflux transporters are often expressed at a baseline level 
and subject to regulations by regulatory proteins (96). The efflux activities of most of efflux 
transport systems rely on the proton motive force as energy source and only ABC 
transporters utilize ATP (98).  
 
    In C. jejuni, a MDR phenotype was related to the expression of efflux proteins in an early 
study (18), but the identities of the overexpressed proteins were not characterized. The 
release of the genome sequence of C. jejuni 11168 facilitated the identification of efflux 
transporters in the bacterium and several efflux transporters have been characterized since 
then (95). A tripartite RND family efflux transporter, named CmeABC, was identified 
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through sequence analysis and transposon mutagenesis (72).  The CmeABC efflux 
transporter is composed of CmeA (periplasmic fusion protein), CmeB (inner membrane 
transporter) and CmeC (outer membrane channel), which are encoded by a three-gene operon 
consisting of cmeA, cmeB and cmeC (72). Experiments with the cmeABC mutant 
demonstrated that the efflux transporter is associated with bacterial intrinsic resistance to a 
variety of antibiotics, bile salts, detergents, and other toxic compounds (72, 110). An 
accumulation assay using ciprofloxacin and ethidium bromide confirmed that CmeABC is 
responsible for the extrusion of antibiotics and toxic compounds (72). The substrates of the 
CmeABC include medically important antibiotics used for Campylobacter therapy, such as 
ciprofloxacin and erythromycin, and the antibiotic additives used in the selective media for 
Campylobacter isolation, such as rifampin, vancomycin and trimethoprim (72). CmeABC in 
conjunction with target mutations, such as mutations in gyrA and 23S rRNA genes, 
contributes to resistance to ciprofloxacin and erythromycin (11, 153). In addition, 
mutagenesis analysis indicated that CmeABC is responsible for Campylobacter resistance to 
bile salts and in vivo colonization in a chicken model, indicating the critical role of CmeABC 
in the adaptation of Campylobacter in the chicken gut (73). CmeDEF is another tripartite 
RND family efflux pump encoded by a three-gene operon in C. jejuni, which is composed of 
an outer membrane protein (CmeD), a membrane fusion protein (CmeE) and an inner 
membrane transporter (CmeF) (2). Mutagenesis studies showed that CmeDEF only 
contributes to a moderate level of resistance to certain antibiotics in C. jejuni (2, 111), but it 
seems that CmeABC and CmeDEF together play an important role in maintaining cell 
viability as a double mutant of CmeABC/CmeDEF failed to grow in culture media (2).  
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    Sequence analysis of C. jejuni genome  also identified several other putative efflux 
transporters and they are Cj0035c (MFS), Cj0390 (SMR), Cj0310 (SMR), Cj0560 (MATE), 
Cj0619 (MATE), Cj1173 (SMR), Cj1174 (SMR), Cj1241 (MFS), Cj1257c (MFS) and 
Cj1687 (MFS) (33, 70). Although limited studies were conducted with some of these 
transporters (33), the functions of these putative transporters remain to be characterized.  
 
    CmeABC is subject to repression by CmeR, a TetR-family regulatory protein encoded by a 
gene immediate upstream of the cmeABC operon (69).  CmeR has a typical HTH (helix-turn-
helix) motif, which can bind to an inverted repeat located in the promoter region of cmeABC 
and serve as a repressor (69). But different from the cases in other bacteria, the repression by 
CmeR is not overcome by most of its substrates and can only be induced by bile salts (71). It 
has been shown that mutations in either CmeR or its binding site result in the overexpression 
of CmeABC and increase the antibiotic resistance in C. jejuni (69).  
 
Prevalence, Sources, and Implications of Antibiotic Resistance 
 
    Antibiotic therapy for Campylobacter infections in humans is effective, and quinolone and 
macrolide antibiotics have been the choices for treatment of human campylobacteriosis. 
Since late 1980’s, antibiotic resistance has emerged as a public health issue due to the failure 
of antibiotic treatments in patients (107). Fluoroquinolone and macrolide antibiotics have 
been utilized in food producing animals (86). It has been controversial wheather the use of 
antibiotics in animal production contributed to the emergence of antibiotic resistant strains in 
humans (107). Multiple publications showed that the use of fluoroquinolones in poultry and 
livestock was associated with the increased fluoroquinolone resistance strains in humans (1, 
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76, 93, 138). In Australia, where the use of fluoroquinolone antibiotics is banned, there is a 
very low prevalence of fluoroquinolone resistance in Campylobacter (136). In cobtrast, in 
countries where fluoroquinolones have been licensed for animal use, there are increased rates 
of isolation of fluoroquinolone resistant Campylobacter strains in both humans and animals 
following the licensure (86).  
 
    Antibiotic resistant Campylobacter strains are widely distributed in poultry and other food 
animals as well as animal food products (14, 64, 81). Broilers carry the highest rates of 
fluoroquinolone resistant C. jejuni strains compared with cattle and pigs (64, 106). In a study 
in Spain, the rates of fluoroquinolone resistant Campylobacter strains from poultry and swine 
were 99% (versus 72% in humans) and a higher percentage of  erythromycin (81%) and 
ampicillin (65.7%) resistant strains were also observed  (118).  It was also reported in the US 
that fluoroquinolone resistant strains emerged since the 1990s after the use of the drug in 
animals was approved (86). Due to the increased isolation of fluoroquinolone resistant strains 
in Campylobacter infections in humans, the FDA has banned the use of fluoroquinolones in 
poultry production since 2005.  
 
    A case study conducted by CDC indicated that the duration of diarrhea was significantly 
longer in patients infected by fluoroquinolone resistant Campylobacter strains (86). There is 
a similar report from Denmark (86). Since Campylobacter spp. are naturally competent, a 
study demonstrated that the mutations for erythromycin resistance can be transferred to 
sensitive strains through natural transformation (58).  Furthermore, recent research indicated 
that fluroroquinonolone resistant Campylobacter strains showed increased fitness in vivo and 
could outcompete sensitive strains in a chicken colonization model (77, 156). There is also 
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evidence that the resistant strains carrying certain mutations can persist without antibiotic 
selection pressure (156), posing a potential long term ecological problem.  
 
Strain Variations, Genotyping and Diagnosis  
 
    Campylobacter spp. have been isolated from diverse sources and serotyping schemes were 
initially used to differentiate Campylobacter isolates and trace the sources of Campylobacter 
transmission.  In C. jejuni, the  heat-stable (HS) antigens have been used in the Penner 
serotyping scheme and the heat-liable (HL) antigens have been used in the Lior serotpying 
scheme since the early 1980s (74, 103). Both serotyping methods have been useful in 
differentiating C. jejuni isolates from human, animal and environmental sources. For 
instance, HS1, HS2 and HS4 serotypes by Penner scheme have been identified in human 
Campylobacter infections in several countries (54, 84, 104).  Due to the cost and the limited 
availability of the antiserum reagents, the use of serotyping has been restricted to a few 
reference laboratories. Furthermore, the existence of high rates of untypable Campylobacter 
strains limited the use of serotyping methods (90). A bacteriophage typing scheme has been 
developed (36), and the combination of serotyping and bacteriophage typing methods 
increased the discriminatory power  (148). Studies on Campylobacter genomic sequences 
and genotyping indicated that LOS/LPS, capsule (major antigenic components for Penner 
typing scheme) and flagella (major antigen for the Lior typing scheme) are subject to 
antigenic variation resulting from horizontal gene transfer, intragenomic rearrangement, or 
phase switching (26).  
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    Genotyping methods have gained popularity in recent years and have become a powerful 
tool in classifying Campylobacter from different sources. Especially since the release of C. 
jejuni genome in 2000, more defined target genes can be selected in the genotyping scheme 
for Campylobacter. Different genotyping methods have been reported and showed higher 
discriminatory power than serotyping. In addition, these methods can also be used to 
differentiate C. jejuni and C. coli strains (91, 92). Genotyping methods reported for 
Campylobacter include AFLP (Amplified Fragment Length Polymorphism), MLST 
(Multilocus Sequence Typing), RFLP (Restriction Length Polymorphism), RAPD (Random 
Amplified Polymorphic DNA) and PFGE (Pulsed-Field Gel Electrophoresis). There are 
variations in some of the molecular typing methods performed in different laboratories 
without standardization. Thus, the data from different laboratories may not be comparable.  
AFLP, fla-PCR RFLP and PFGE have been selected for standardization in Europe by 
Campynet, which provides standardized molecular methods and databases for the studies on 
Campylobacter infections in the European Union (28). PFGE has been selected for 
standardization by PulseNet, a US-based molecular typing network for foodborne pathogens, 
in an attempt to standardize PFGE protocol (28).  
 
    Due to the genomic plasticity of Campylobacter caused by horizontal gene transfer, 
genomic rearrangement and phase variation, the results from the molecular typing methods, 
such as AFLP, fla-RFLP and PFGE, can be confounded because these genotyping methods  
are all based on band patterns, which are sensitive to local and genome-wide changes (26). 
Multilocus enzyme electrophoresis (MEE) is a method initially developed for bacterial 
population genetics, in which variations are measured by the mobility of metabolic core 
enzymes in electrophoresis. Later the method was evolved to compare the DNA sequences of 
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genetic loci for the core enzymes, which is the Multilocus sequence typing (MLST). MLST 
also has a high discriminatory power comparable to other molecular genotyping methods, 
such as PFGE, and recent studies demonstrated that the results from MLST are portable and 
comparable among different laboratories (24, 25).  
 
Prevention and Control 
 
    Since poultry has been recognized as a major reservoir of Campylobacter for human 
Campylobacter infections, numerous studies have targeted the interruption of Campylobacter 
transmission from poultry to humans. Intervention of Campylobacter transmission at the 
postharvest stage has been proposed at slaughter and meat processing plants through the 
PR/HACCP (Pathogen Reduction/Hazardous Analysis and Critical Control Point) system 
implemented by the USDA (157). By implementing PR/HACCP, pathogens are eliminated or 
reduced mainly through physical and chemical treatments, such as heat and organic acid 
treatments. The control of foodborne pathogens in the food processing by PR/HACCP was 
first developed for E. coli O157 H:7 and then Salmonella. Since Salmonella is also a 
common foodborne pathogen present on chicken meat, it was expected that the 
implementation of PR/HACCP would contribute to the reduction of both Salmonella and 
Campylobacter. It has been reported that PR/HACCP has been playing a significant role in 
reducing Salmonella in chicken meat, but Campylobacter contamination has not been 
effectively reduced on the chicken meat. Because chickens carry high numbers of 
Campylobacter in the intestines, contamination and spread of Campylobacter during 
slaughter and evisceration may be a key problem. Therefore, many researches have been 
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focused on the intervention of Campylobacter colonization in chickens at the preharvest 
stage.   
 
    Biosecurity and sanitation have been practiced in the control of Campylobacter infections 
in chicken flocks (34). Measures, such as thorough cleaning and disinfection and change of 
footwear have been reported effective in the prevention of acquiring Campylobacter from the 
outside environment and the spread of Campylobacter inside the flock (34, 137). But good 
and effective biosecurity may not be easily followed on a routine basis (34). Although 
chickens become infected by Campylobacter from environmental sources, biosecurity 
measures will be more effective if specific sources or known risk factors of Campylobacter 
infection are targeted (34). 
 
    Competitive exclusion (CE) to limit Campylobacter colonization in chicken intestines has 
been studied using normal gut flora and probiotic anaerobic bacteria. It is thought that CE 
works through the generation of bactericidal products, such as organic acids, or through 
nutritional competition. The effects of CE have been reportedly successful in some studies 
(127), but variable in others (63). Recently, bacteriocins extracted from Bacillus circulans, 
Paenibacillus pylomyxa and Lactobacillus salivarius have been experimentally shown to 
reduce Campylobacter colonization in broilers and turkey poults significantly (19, 130, 131). 
If successful, bacteriocins could be used to reduce the Campylobacter loads in the intestines 
of broilers and turkery before slaughtering.   
 
    Bacteriophage have shown promise in treating other bacterial infections, but no 
commercial product is available (147). Although recent study showed that bacteriophage is a 
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promising tool in preventing or reducing Campylobacter colonization in chickens (147), but 
additional research is needed to evaluate the dosage, bacterial resistance,  bacteriophage 
dynamics and ecology in chickens (20, 75, 147). The large number of un-typable 
Campylobacter by bacteiropahges poses an additional chanllenge to the control of 
Campylobacter colonization in chickens using bacteriophages.   
 
    The control of Campylobacter colonization in chickens through vaccination has been 
expected to be a feasible approach.  An inactivated Campylobacter whole cell vaccine can 
stimulate mucosal IgA response in chickens (114). Antibodies administered passively or 
preincubated with Campylobacter significantly reduced bacterial colonization in chicken 
intestines (129, 134). Campylobacter flagellin has been identified as a major protective 
antigen (67) and some outer membrane proteins, such as the 67kD protein, were also shown 
to be protective antigens as well (151).  Immunization of 24-day old young chickens with an 
inactivated vaccine resulted in a significant reduction in intestinal colonization, but the 
immunization in one-day old birds had poor protection due to the immaturity of immune 
system in early age (150). It has been anticipated that an effective vaccination must be able to 
prevent chicken colonization at an early age and this approach seems impractical due to the 
immaturity of chicken immune systems at this age. Also it was speculated that it will be 
impractical to vaccinate the chickens to eliminate the bacterium from the intestines when the 
birds have already been colonized (146). 
 
    There has long been a desire to develop a Campylobacter vaccine for humans at high risk 
of Campylobacter infections, such as travelers and military recruits stationed overseas. 
Inactivated Campylobacter whole cell vaccine is not appropriate due to the potential of 
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causing autoimmune disease, such as Guillain-Barré syndrome. Flagellin expressed on a 
recombinant E. coli strain is a promising candidate for a subunit vaccine, but the major 
immunogenic portion of the flagella is subject to high antigenic variations and the unique 
glycosylation for flagellin in Campylobacter is critical for serotyping and immunogenicity 
(67). Recently multiple surface antigens have been identified by a proteomic technique and 
some of them showed the potential as vaccine candidates (109).  However, these antigens 
have not been formally evaluated by vaccination studies. At this stage, no commercial 
vaccines against Campylobacter are available for animals or humans. 
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Abstract 
 
    CmeABC, a multidrug efflux system in Campylobacter jejuni, plays an important role in 
antimicrobial resistance and intestinal colonization. Although this efflux system has been 
well characterized in C. jejuni, it is unknown if CmeABC homologs are also present and 
functional in other Campylobacter spp. In this study, various approaches were utilized to 
identify and characterize the CmeABC homologs in Campylobacter coli, Campylobacter 
lari, Campylobacter upsaliensis, and Campylobacter fetus. PCR and sequence results 
indicated that the cmeABC homolog is present in the five Campylobacter spp. and the 
genomic organizations of the cmeABC operons are similar to that in C. jejuni. Although the 
cmeB sequence is highly homologous between C. jejuni and C. coli, greater sequence 
divergence was observed between thermophilic Campylobacter and other Campylobacter 
spp. In addition, the sequences of CmeA and CmeC are more variable than that of CmeB 
among the five species. Consistent with the sequence results, immunoblotting using 
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CmeABC specific antibodies demonstrated that this efflux system is expressed in the 
Campylobacter spp., but shows antigenic variations among different species. Insertional 
mutagenesis of cmeB increased the susceptibility of Campylobacter to structurally diverse 
antibiotics in the five Campylobacter spp. examined in this study.  Together, these results 
indicate that CmeABC is widely distributed among different Campylobacter spp. and plays 
an important role in Campylobacter resistance to various antibiotics.  
 
Introduction 
 
    Multidrug efflux pumps have been recently recognized as a major mechanism responsible 
for the intrinsic and acquired antibiotic resistance in many bacterial species (19, 37, 41, 45). 
The multidrug efflux pumps are membrane transport proteins which belong to several super 
families, including the ATP binding cassette (ABC) superfamily; the resistance, nodulation 
and cell division (RND) superfamily; the major facilitator superfamily (MFS); the small 
multidrug resistance (SMR) family; the multidrug and toxic compound extrusion (MATE) 
family (13, 41).  A RND efflux pump is a tripartite component system, including an inner 
membrane transporter, a periplasmic membrane fusion protein, and an outer membrane 
channel protein (41),  which can form a channel across the Gram-negative bacterial inner and 
outer membranes. Many of the efflux pumps identified in Gram-negative bacteria fall into the 
RND superfamily (34). Due to the complex nature of Gram-negative bacterial cell wall, 
permeability across the cell wall is relatively low (35). The RND efflux systems extrude 
antimicrobials and toxic compounds directly out of the bacterial cells (40). The RND efflux 
pumps have been identified in many medically important bacterial species and are associated 
with the intrinsic and acquired resistance to various antimicrobials (40).  
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    Campylobacter spp., primarily Campylobacter jejuni, have been incriminated as one of the 
leading foodborne pathogens in the developed countries (2, 30). Other Campylobacter spp., 
such as Campylobacter coli, Campylobacter upsaliensis, Campylobacter lari, and 
Campylobacter fetus, have also been increasingly identified as the causes of gastrointestinal 
infections or other clinical diseases (3, 29, 39). C. jejuni causes the majority of the 
gastroenteritis in humans and is mainly transmitted via the consumption of contaminated 
food and water. Gastroenteritis caused by Campylobacter can be self-limiting, but medical 
attention including antibiotic treatment is needed in severe cases, such as those occurring in 
immunoincompetent patients (46). Recently, the development of antibiotic resistance in 
Campylobacter has significantly reduced the effectiveness of antibiotic therapy and has 
emerged as a major public health problem worldwide (9, 49).  
 
    Multiple mechanisms have been associated with antibiotic resistance in Campylobacter, 
but target mutations and efflux are the two major mechanisms that have been well 
characterized (14, 26, 31). In C. jejuni, the RND family efflux pump CmeABC has been 
identified and experimentally characterized to be a major efflux pump for structurally 
diversified antimicrobials and toxic compounds (22, 44). Even though other putative efflux 
pumps have also been identified in C. jejuni through genomic sequence analysis, so far 
CmeABC is the only experimentally confirmed efflux system in Campylobacter. CmeABC 
has been associated with both the intrinsic and acquired resistance to antimicrobials in 
Campylobacter (26, 40, 51). More intriguingly, CmeABC is involved in the efflux of bile 
salts and plays a critical role in the colonization of chickens (23). Unlike the cases with other 
bacterial species, such as Pseudomonas aeruginosa, in which there are multiple efflux pumps 
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for different and overlapping substrates, CmeABC is the only major player in C. jejuni in the 
extrusion of antimicrobials and toxic compounds (1, 10, 28, 51).  It was also demonstrated 
that, although CmeABC is constitutively expressed at a baseline level, it is repressed by 
CmeR encoded by an adjacent gene (25). The expression of CmeABC can be induced by bile 
salts, but not by the other antimicrobial substrates of the efflux pump (21). Since bile salts are 
present in the intestinal tract, where Campylobacter colonizes, it is anticipated that the 
expression of CmeABC is elevated in vivo, which has been confirmed in ileal loops of rabbits 
examined in a microarray study (21).  
 
    Although the genetic features and functions of CmeABC have been well defined in C. 
jejuni, it is unknown if this efflux pump is also present and functional in the same fashion in 
other Campylobacter spp.  The purposes of this study were to identify the orthologs of 
CmeABC in different Campylobacter spp. and to characterize the expression and function of 
CmeABC in these species. We found that the orthologs of CmeABC were identified in all 
five species of Campylobacter examined in this study, share conserved genomic 
organizations and protein domains, and function similarly in the resistance to antimicrobials. 
(This work has been partially presented at the 105th ASM General Meeting in Atlanta, GA in 
2005). 
 
Materials and Methods 
 
    Bacterial strains and cultures. The bacterial strains of the five species of Campylobacter 
used in this study are listed in Table 1. Campylobacter strains were grown in Mueller-Hinton 
(MH) broth or on MH agar plates at either 37 °C (for C. upsaliensis, C. lari, and C. fetus) or 
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42 °C (for C. jejuni and C. coli) under microaerobic conditions. For the culture of C. 
upsaliensis, C. lari, and C. fetus, the Mueller-Hinton broth or agar plates were supplemented 
with either Campylobacter Growth Supplement (Oxoid) or 5% horse blood (Cleveland 
Scientific).  For the selection and culture of the cmeB insertional mutants in different 
Campylobacter spp., either 4 μg/ml of chloramphenicol or 20 μg/ml of kanamycin was added 
to the corresponding culture media depending on the antibiotic resistance cassette inserted in 
the mutants. Escherichia coli JM109 was routinely grown in Luria-Bertani (LB) medium. For 
the selection of E. coli transformants, the LB medium was supplemented with a final 
concentration of 30 μg/ml of kanamycin or 20 μg/ml of chloramphenicol, and 100 μg/ml of 
ampicillin according to the selection marker(s) carried on the plasmid. 
 
    DNA extraction and plasmid purification. Campylobacter genomic DNA was extracted 
with the Wizard® Genomic DNA Purification Kit (A1121, Promega) following the 
manufacturer’s instruction with minor modifications. Briefly, 100 μl of 24 or 48 hr 
Campylobacter culture in MH broth or MH broth with Campylobacter Supplement (Oxiod) 
was inoculated onto MH agar or MH agar with Campylobacter Growth Supplement or 5% 
horse blood plates. Campylobacter cells were harvested after 24 ~ 48 h incubation and 
centrifuged (10,000 × g for 1 min). Cell pellets were suspended in 600 μl of Nuclei Lysis 
Buffer provided in the Kit and incubated (80 °C for 10 min). The cell lysates were cooled at 
room temperature, and then 3 μl of RNase provided in the kit was added and incubated at 37 
°C. Cellular proteins were precipitated by adding the Protein Precipitation Solution from the 
Wizard® Genomic DNA Purification Kit and removed by centrifugation (12,000 × g for 3 
min). The aqueous phase containing genomic DNA was added to an equal volume of 
isopropanol. Genomic DNA was harvested by centrifugation or collected with a glass rod, 
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washed twice with 70% ethanol, dried at room temperature for 15 min, and dissolved in 
deionized water. E. coli plasmids were extracted from overnight cultures in LB broth 
supplemented with appropriate antibiotics using the Plasmid MiniPrep Kit (Qiagen) 
following the manufacturer’s instructions.  
 
    DNA sequencing strategies and primer design. PCR-based sequencing in conjunction 
with chromosome walking was used in determining the sequences of the cmeABC in various 
Campylobacter spp. cmeABC-specific primers were designed from the sequences of C. jejuni 
11168 and 81-178 deposited in the Gene Bank database. For the initial sequencing of 
cmeABC operon in C. upsaliensis, C. lari, and C. fetus, pairs of degenerate primers for a 
fragment of the cmeB gene were designed and the amplified DNA was cloned and sequenced 
on pGEM-T plasmid. Then the cmeABC sequences in these Campylobacter spp. were 
acquired through chromosomal walking. Primers used in the sequencing reactions are listed 
in Table 2. DNA Sequencing was performed at the Iowa State University DNA Facilities. 
 
    Polymerase chain reaction (PCR). PCR was performed in a reaction volume of 50 μl 
containing 200 nM each of the deoxynucleoside triphosphates (dNTPs), 2.0 mM of  MgCl2, 
200 nM each of the primers, 50~100 ng of template DNA, and 2.5 units of the Taq 
polymerase (Promega) or the Pfu Turbo polymerase (Stratagene). PCR cycling conditions 
were determined according to the estimated annealing temperatures of the primers and the 
length of the amplified products. PCR products for DNA sequencing and cloning were 
purified using a commercial PCR purification kit (Qiagen). 
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    Mutagenesis of the CmeABC efflux pump.  The cmeB mutant was generated for each 
Campylobacter spp. through the insertion of a chloramphenicol (cat) or kanamycin (kan) 
resistance cassette in the cmeB gene based on the previously published method with minor 
modifications (1). In the first step of the mutagenesis, a suicide vector carrying either a cat or 
kan cassette flanked by 0.5 to1.2 kb of the cmeB fragments was constructed. Briefly, the cat 
or kan cassette was amplified using the Pfu polymerase (Stratagene) from pUOA18 (cat 
cassette) or pMW10 plasmids (kan cassette) and purified by the PCR purification kit 
(Qiagen). The cmeB gene was amplified by the Taq polymerase (Promega) with primers 
listed in Table 2 and cloned into the pGEM-T vector (Promega). The antibiotic cassette was 
inserted into the cmeB sequence by direct ligation or an inverse PCR method. For the direct 
ligation method, the amplified flanking cmeB fragments and the antibiotic cassette were 
treated with restriction enzymes and then ligated by T4 DNA ligase (Promega). The ligated 
DNA was purified by agarose gel electrophoresis. The DNA band of the expected size was 
excised and was ligated to pGEM-T (Promega) through A-T cloning. For the inverse PCR 
method, the cmeB DNA was amplified by the Taq polymerase and cloned into pGEM-T, 
which was then transformed into E. coli JM109 cells. The purified pGEM-T constructs were 
used as templates in the reverse PCR using the Pfu polymerase and a pair of cmeB inverse 
PCR primers listed in Table 2. The amplified DNA was ligated to the antibiotic cassette by 
T4 DNA ligase, resulting in a suicide vector carrying the antibiotic cassette flanked by the 
cmeB sequences. The suicide vectors were transformed into Campylobacter cells via 
electroporation according to the protocol described by Guerry and coauthors (12). After 
overnight incubation on a non-selective MH agar plate, the electroporated cells were plated 
onto selective MH agar plate with appropriate antibiotics and incubated for 3 ~ 5 days 
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microaerobically at 42°C. Single colonies of transformants were obtained and the cmeB 
insertional mutations were confirmed by PCR. 
 
    MIC tests on Campylobacter strains and mutants. The broth microdilution method was 
used to measure minimal inhibitory concentration (MIC) of various antibiotics as described 
previously (15, 22). Fresh Campylobacter cultures grown for 24 ~ 48 hours in MH or MH 
with Campylobacter Growth Supplements (Oxiod) were used as inocula. Two-fold dilution 
series of antibiotics or chemicals in 50 μl of the same bacterial culture medium were made in 
96-well plates. Fifty microliter Campylobacter culture containing 5×105 CFU cells/ml was 
added to the 50 μl of diluted antibiotics or chemicals in the 96-well plates and mixed by 
gentle shaking. The inoculated plates were incubated at 37 °C (C. upsaliensis, C. lari and C. 
fetus) or 42 °C (C. jejuni and C. coli) for 48 hours under microaerobic conditions. 
 
    Western blotting analysis of the CmeABC proteins. Bacterial membrane fractions were 
prepared as described previously and total proteins were quantified by using the BCA kit 
(Pierce). Membrane fractions were separated on 10% SDS polyacrylamide gels and 
transferred to nitrocellulose membranes as described (22). The blotted membrane was 
blocked with 5% skimmed milk and sequentially stained with anti-CmeABC antibodies and 
the peroxidase-labeled goat-anti-rabbit secondary antibodies. Anti-CmeA, -CmeB and -
CmeC antibodies were prepared in a previous study by the immunization of rabbits with 
recombinant CmeA, CmeB and CmeC proteins from C. jejuni (22).  Horseradish peroxidase 
labeled anti-rabbit secondary antibody was purchased from KPL (Gaithersburg, MD). 
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    Sequence assembly and analysis.  The obtained DNA sequences were assembled and 
analyzed using the Omega 2.0 software. The analysis of sequence homology and alignments 
were performed with AlignX (Invitrogen). Protein motifs were predicted using the W2H 
program of the GCG package maintained at the Iowa State University 
(http://deepc2.psi.iastate.edu/w2h/). Transmembrane fragment prediction was performed with 
the TMHMM Sever v. 2.0 (www.cbs.dtu.dk/services/TMHMM/). Lipoprotein signal 
sequences were predicted using the LipoP 1.0 Server 
(http://www.cbs.dtu.dk/services/LipoP/). 
 
Results 
 
    Sequencing strategies and assembly of the cmeABC homologs in different 
Campylobacter spp. Campylobacter strains that were sequenced for the cmeABC operon 
included C. jejuni S3b; C. coli 993868, C. coli 33559, C. coli TF 1-13, C. coli H-8, C. 
upsaliensis 2744, C. lari 3121, C. lari 3125, C. fetus 5652, and C. fetus 6953 (Table 1). PCR 
amplification and sequencing of the cmeABC homologs in C. jejuni, C. coli, C. upsaliensis, 
C. lari and C. fetus were initiated using primers designed from the published sequences of 
the cmeABC operon of C. jejuni 81-176 and NCTC 11168.  PCR reactions with the C. jejuni 
cmeABC primers were only successful in the amplification of the cmeABC operon of C. 
jejuni S3b and the cmeB gene in the C. coli strains. Then additional gene specific and 
degenerate primers were designed based on the highly conserved regions in C. jejuni and C. 
coli to amplify the cmeB in C. upsaliensis, C. lari and C. fetus. A fragment of C. upsaliensis 
cmeB was successfully amplified by the primer pair of cmeB2654F and cmeB3021R (Table 
2) and was sequenced directly.  The cmeB in C. lari and C. fetus was successfully amplified 
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only by a pair of degenerate primers, cmeB1213F and cmeB2817R (Table 2). The amplified 
cmeB DNA were cloned into pGEM-T vector and sequenced by using vector primers. The 
remaining of sequences of the cmeABC homologs in C. coli, C. upsaliensis, C. lari and C. 
fetus, which could not be amplified for sequencing by PCR, but were acquired in each 
Campylobacter spp. through chromosomal walking, in which chromosomal DNA were used 
as templates in the sequencing reactions using cmeB-specific primers. All of the sequences 
were assembled based on the overlapping homologous regions of each sequenced DNA 
fragment by using Omega 2.0 software. Sequences from the plasmid clones were 
subsequently confirmed by PCR amplified genomic DNA. After the first sequences of 
cmeABC homolog of C. coli, C. lari and C. fetus were obtained, specific primers were 
designed based on the known sequences in each species and PCR based sequencing was 
performed to acquire cmeABC sequences of C. coli 33559, C. coli TF1-13, C. coli H-8, C. 
lari 3121, C. lari 3125, C. fetus 5652 and C. fetus 6953.  
 
    The genomic organization of the cmeABC operon in different Campylobacter spp.  
The homologs of CmeABC, which is a RND efflux pump previously identified in C. jejuni 
(22), were identified in all of the Campylobacter spp. examined in this study by using PCR 
and genomic DNA sequencing. As showed in Fig. 1, the genomic organization of the 
cmeABC homologs in C. jejuni, C. coli, C. upsaliensis, C. lari and C. fetus is conserved in 
terms of the orientation and the order of the three genes in the operon. Upstream the cmeABC 
operon, homologs of CmeR, a local regulator of CmeABC in C. jejuni (20, 21), were 
identified in all of the Campylobacter spp. examined. Downstream the cmeABC operon, 
homologs of cj0364 in C. jejuni were also identified in C. coli and C. upsaliensis. The 
downstream sequence of the cmeABC operon in C. lari was short  and the encoded amino 
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acid sequence (73 amino acids) shares 45% homology in identity with Cj1021c (putative 
periplasmic protein)  in C. jejuni NCTC 11168. The downstream gene of CmeABC in C. 
fetus does not have homology with any C. jejuni proteins.  
 
    Comparison of the cmeABC operon in different Campylobacter spp.  The cmeA, cmeB 
and cmeC genes were arranged in tandem with cmeA and cmeB overlapping 1 nucleotide and 
cmeB and cmeC overlapping 8 nucleotides, except that in C. lari, cmeB and cmeC overlap by 
29 nucleotides. The G+C content of the cmeABC operon in the different Campylobacter spp. 
ranged from 31.7% to 36.2% and the G+C content of the cmeABC in C. jejuni NCTC 11168 
strain (33.1%) was slightly higher than the average  G+C content (30.6%) of the whole 
genome (36).  The intergenic regions between the cmeABC operon and the upstream cmeR 
were 82 to 129 nucleotides. 
 
    The inner membrane transporter of the RND family efflux pump is responsible for the 
substrate recognition and extrusion and is composed of 12 transmembrane fragments with 
two large periplasmic loops between the 1st and the 2nd, the 7th and the 8th transmembrane 
fragments (8, 47). Structural prediction of transmembrane fragments by using TMHMM 
Server v. 2.0 indicated the predicted structural features of CmeB were conserved among the 
Campylobacter spp. Sequence alignment of CmeB homologs from different species showed 
that the homologous regions are predominantly located in the transmembrane fragments. The 
periplasmic loops are more variable than the transmembrane fragments. The majority of the 
variations in the loop regions are amino acid substitutions instead of insertions or deletions. 
The translated sequences of CmeB homologs had 1040 amino acids in C. jejuni, C. coli and 
C. lari; 1041 amino acids in C. upsaliensis; and 1048 amino acids in C. fetus. The additional 
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amino acid in the CmeB of C. upsaliensis is an insertion of glycine at position 598, which is 
located in the second periplasmic loop. Four of the additional amino acids in the CmeB of C. 
fetus (both C. fetus 6953 and 5253) are an insertion of PGEA between amino acid 636 and 
639, which is also located in the second periplasmic loop. The other four additional amino 
acids in the CmeB of C. fetus are at the end of the CmeB peptide chain.  The CmeA and 
CmeC homologs in the Campylobacter spp. are all predicted to be lipoproteins with a highly 
conserved lipoprotein cleavage sites.  
 
    Pairwise alignments of the CmeABC sequences from the Campylobacter strains in each 
species showed that the CmeA, CmeB and CmeC are highly conserved between strains 
within the individual species with amino acid identity ranging from 95% to 100%. (Table 
3.1, 3.2, 3.3). Pairwise comparisons of CmeABC sequences in C. jejuni with the non-jejuni 
species showed their relatedness to C. jejuni in the order of C. coli, C. upsaliensis, C. lari and 
C. fetus, which is consistent with the phylogenetic prediction based on the 16S rRNA 
sequences in the Campylobacter spp. Homologies of CmeA between C. jejuni and non-jejuni 
Campylobacter spp. are 80% - 86% (C. coli), 64% (C. upsaliensis), 55% (C. lari), and 43% 
to 44% (C. fetus). Homologies of CmeB between C. jejuni and non-jejuni Campylobacter 
spp. are 93% - 98% (C. coli), 76% (C. upsaliensis), 74% - 75% (C. lari) and 60% (C. fetus). 
Homologies of CmeC between C. jejuni and non-jejuni species are 85% - 86% (C. coli), 60% 
(C. upsaliensis), 54% - 55% (C. lari), and 35% (C. fetus). Among the three genes in the 
cmeABC operon, CmeB was the most conserved and CmeC was the least conserved among 
the examined Campylobacter spp. 
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    Features of CmeR in different Campylobacter spp.  CmeR was identified as a local 
repressor of the CmeABC efflux pump in C. jejuni and it is encoded by the cmeR gene 
located upstream cmeABC (20). In this study, the homolog of CmeR was identified in all of 
Campylobacter spp. examined with exception in C. fetus strain 5652, in which the CmeR was 
truncated at amino acid 91. Sequence alignment of the deduced amino acid sequences of the 
CmeR homologs indicated that CmeR is more divergent than the CmeABC proteins across 
the Campylobacter spp., but a rather conserved helix-turn-helix (HTH) motif was identified 
in the N terminal region of the CmeR proteins. The HTH motif is responsible for the binding 
of CmeR to the inverted repeat located in the cmeABC promoter region (20). Sequence 
analysis of the intergenic region between cmeR and cmeABC revealed a typical inverted 
repeat in the non-jejuni Campylobacter spp., which is almost identical to the one in C. jejuni. 
Thus, it is likely that the HTH motif of CmeR in the non-jejuni Campylobacter spp. can bind 
to the inverted repeat in the promoter region of the cmeABC operon to regulate the 
expression of CmeABC.  
 
    Expression of cmeABC in different Campylobacter spp.   Campylobacter whole cell 
proteins and cell membrane fractions were used to determine the expression of CmeABC by 
Western blotting analysis. As shown in Fig. 3, CmeA, CmeB and CmeC proteins were 
identified in all strains of the C. jejuni, C. coli, C. upsaliensis and C. lari examined in the 
study, but not in the C. fetus strains (data not shown). The sizes of the CmeA, CmeB and 
CmeC measured by the Western blotting were consistent with the predicted molecular mass 
from the amino acid sequences except the C. lari CmeA, which was smaller than the 
expected size.  CmeB and CmeC were absent in the cmeB mutants of all strains of C. jejuni, 
C. coli, C. upsaliensis and C. lari (data not shown). Since cmeA, cmeB and cmeC are 
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clustered together forming a three-gene operon, the insertion of an antibiotic resistance 
cassette in the cmeB gene resulted in a polar effect and interfered with the transcription of 
cmeC in the cmeB mutants. This polar effect of cmeB insertional mutagenesis on CmeC 
expression was consistent with the finding in a previous study with C. jejuni (22). As shown 
by the Western blotting analysis (Fig. 2), the differences in staining intensity of the CmeABC 
proteins in different Campylobacter spp. reflected antigenic variations caused by the 
divergence in amino acid sequences of the CmeABC proteins among the Campylobacter spp. 
because the antibodies used in the Western blotting were made from C. jejuni CmeABC.  
 
    Mutation of cmeB increases the susceptibility of different Campylobacter spp. to 
structurally unrelated antibiotics and chemicals. The mutagenesis of cmeB in non-jejuni 
Campylobacter spp. by natural transformation using genomic DNA of the cmeB mutants of 
C. jejuni 11168 and 81-176 was not successful, probably due to the heterogeneity of cmeB 
sequences. Thus, the cmeB mutants in other Campylobacter spp. were made via insertional 
mutagenesis and homologous recombination. The cmeB mutants were successfully made in 
C. jejuni S3b, C. coli 993868, C. coli TF1-13, C. upsaliensis 2744, C. lari 3121, and C. fetus 
5262. A C. jejuni 700819 cmeB mutant was generated through natural transformation with 
genomic DNA of the C. jejuni 11168 cmeB mutant. 
 
    The mutagenesis of CmeB resulted in substantial increases in the susceptibility of all 
Campylobacter spp. to the majority of antibiotics and toxic compounds examined (Table 4.1 
and 4.2). There were 8- to 16- and 4- to-64 fold changes in the MICs of ciprofloxacin and 
erythromycin, respectively. The changes in the MICs to tetracycline were also substantial 
from 2- to 16-fold. The resistance to gentamicin was slightly affected by the CmeABC 
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mutation in C. jejuni and C. coli with a 2-fold change in the MIC, but not changed in C. 
upsaliensis, C. lari and C. fetus. CmeABC mutations were also shown to affect the resistance 
to ampicillin in different Campylobacter spp., with 2~16-fold changes in the MIC.  
     
    Consistent and drastic changes (16~512-fold) in MIC of cefotaxime were observed in the 
cmeB mutants. Different from the case with cefotaxime, the intrinsic resistance of the 
Campylobacter spp. to cephalothin and cefoperazone was much higher than to cefotaxime. 
Mutation of CmeABC drastically decreased the resistance to cephalothin and cefoperazone in 
all of the Campylobacter spp. Mutation of CmeABC has been shown to cause a dramatic 
decrease in the MIC of rifampin in C. jejuni (22). Similar findings were observed in this 
study with C. coli, C. upsaliensis, and C. lari; however, no changes in the MIC of rifampin in 
the CmeABC mutant of C. fetus were observed. Together, these results indicate the CmeABC 
efflux pump is a major mechanism involved in the resistance to cefotaxime, cephalothin, 
cefoperazone and rifampin in the Campylobacter spp. with exception for the rifampin 
resistance in C. fetus.  
 
    The CmeABC mutants were also more susceptible than the wild-type strains to cholic acid, 
SDS and ethidium bromide, which is in agreement with our previous finding with C. jejuni 
(22). Based on these findings, it can be concluded that the CmeABC efflux system is an 
important player in the intrinsic resistance to antibiotics and toxic compounds in all five 
Campylobacter spp.  
 
Discussion 
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    CmeABC has been previously characterized in C. jejuni (21-23, 25, 44). This study was 
initiated in an attempt to identify the homologs of the CmeABC efflux transport system in 
non-jejuni Campylobacter spp.. By using genomic sequencing strategy and immunoblotting, 
the homologs of the CmeABC efflux transport system were identified in C. coli, C. 
upsaliensis, C. lari and C. fetus. DNA sequence comparison and analysis indicated that the 
genomic organizations of the CmeABC homologs are uniformly conserved, but sequence 
polymorphisms were identified in the tripartite components of the efflux transport system 
among the Campylobacter spp. examined. By insertional mutagenesis, it was shown that the 
CmeABC homologs in different Campylobacter spp. function similarly as in C. jejuni and 
are associated with the intrinsic resistance to diverse antibiotics and toxic compounds. 
 
    Most RND efflux pumps are encoded on bacterial chromosomes. The genes encoding the 
periplasmic fusion protein and the inner membrane transporter are clustered together in 
nearly all of the bacterial RND efflux systems (43). But the gene encoding the outer 
membrane protein can be either attached to the other two genes, such as the OprM of MexAB 
in Pseudomonas aureginosa (43), or located elsewhere in the genome, such as the TolC of 
AcrAB in E. coli  (27).  The three genes encoding the CmeABC efflux system have the same 
genomic organization in all five Campylobacter spp. The flanking regions of the CmeABC 
operon in different Campylobacter spp. are also conserved as revealed in this study. 
Immediately upstream the cmeABC operon, the homologs of CmeR, a regulator of CmeABC 
identified in C. jejuni, were identified in the Campylobacter spp., and they all have a 
conserved helix-turn-helix (HTH) motif of  the TetR family regulator proteins (20). 
Furthermore, conserved DNA sequences of an inverted repeat, identified previously in C. 
jejuni as the binding site for CmeR (20), were identified in the promoter regions of all of the 
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CmeABC operons in the Campylobacter spp. These findings suggest that CmeABC in C. 
coli, C. upsaliensis, C. lair and C. fetus are regulated by CmeR in a similar manner, which 
will be examined in the future studies. 
 
        The RND super family efflux pumps identified in bacteria are the major MDR efflux 
pumps involved in intrinsic and acquired resistance to antimicrobials (37, 38, 41, 42).  By 
forming a channel across bacterial cell wall through its three components, RND efflux 
transport systems confer on Gram-negative bacteria an additional advantage over other efflux 
transporters (41, 42). The findings from our functional studies on the CmeABC homologs 
using the knockout mutants of different Campylobacter spp. agree with our previous results 
that the CmeABC is associated with intrinsic resistance to structurally diverse antibiotics, 
bile salts, detergents, and other toxic compounds (22, 23, 44). The inner membrane 
transporter of the RND efflux system is responsible for the substrate specificity, and the 
periplasmic loops of RND efflux transporter are associated with substrate binding specificity 
(8, 47). Sequence homologies of the CmeB from different species compared with C. jejuni 
are 93~99% (C. coli), 76% (C. upsaliensis), 74% (C. lari) and 60% (C. fetus). Compared 
with CmeB, the sequences of CmeA and CmeC among the Campylobacter spp. are more 
divergent, which are likely more involved in interacting with inner membrane protein and 
other outer membrane structures in forming a channel across the cell wall.  The sequence 
variations in the CmeB homologs of different Campylobacter spp. mostly fell into the two 
predicted periplasmic loops. Therefore, the variations of CmeB in the loop regions may result 
in the functional differences in the resistance profiles (e.g. rifampin and cephalosporins) in C. 
upsaliensis and C. fetus as shown in the CmeB knockout mutants.  However, the MIC test 
results indicated that the overall antimicrobial resistance profiles associated with the 
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CmeABC efflux pumps in different Campylobacter spp. are highly conserved, indicating that 
CmeABC may have been selectively preserved during the evolutionary process. This 
findings is consistent with the observations from the studies on MDR efflux pumps (37). 
 
    It has also been shown experimentally that CmeABC works synergistically with target 
point mutations and confers high levels of resistance to ciprofloxacin and erythromycin (6, 7, 
28). CmeABC is also involved in the emergence of ciprofloxacin resistance in C. jejuni 
during drug treatment by lowering the antibiotic level inside the bacterial cells (26, 48). The 
overexpression of CmeABC, which is associated with a  MDR phenotype in C. jejuni, can 
result from the mutations of CmeR or its binding sites in the cmeABC promoter region, or the 
induction by inducers, such as bile salts (5, 20, 21). Since the CmeABC homologs in the non-
jejuni Campylobacter spp. function similarly in the resistance to antimicrobials, the 
CmeABC homologs are likely to have a similar influence on the antibiotic resistance in the 
non-jejuni Campylobacter spp.  
 
    Campylobacter is intrinsically resistant to some cephalosporins and rifampin and these 
antibiotics are often used as selective agents in the isolation of Campylobacter spp., 
especially C. jejuni and C. coli (4, 11, 16). The intrinsic resistance of Campylobacter to 
cephalosporin has been attrbuted to the low binding affinity of cephalosporins to the bacterial 
penicillin binding protein or the low permeability of cell membrane (17). The resistance 
mechanism to rifampin reported in other bacteria is mediated by the target mutations in DNA 
dependent RNA polymerase (RpoB) (32), but the mechanism of rifampin resistance in 
Campylobacter is unknown. The Campylobacter spp. included in this study all showed high-
level resistance to cephalothin, cefoperazone and rifampin, as well as cefotaxime, except C. 
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upsaliensis which has low tolerance to these antibiotics. In the CmeABC knockout mutants, 
the MICs to cephalothin, cefoperazone, cefotaxime and rifampin decreased dramatically, 
except in C. fetus in which CmeABC knockout did not affect rifampin resistance. Therefore, 
we concluded that the CmeABC efflux system is the main mechanism associated with the 
high-level resistance to cephalothin, cefoperazone and rifampin, and the moderate resistance 
to cefotaxime in different Campylobacter spp. The mechanism responsible for high-level 
rifampin resistance in C. fetus could be due to another efflux pump, low membrane 
permeability, or mutations in RpoB, which remains to be determined.   
 
    Several antibiotics, such as rifampin, cephalothin and cefoperazone, have been 
incorporated to commercial Campylobacter selective media for the isolation of 
Campylobacter spp. from clinical samples (33). Our results in this study indicate that 
CmeABC is responsible for the high-level instrinsic resistance to these antibiotics and 
provide an explanation why these antibiotics can be used in the selective media. In addition, 
results from this study also revealed that C. upsaliensis appears to be intrinsically more 
susceptible to the antibiotics, which highlights the need to lower the concentration of 
antibiotics in selective media to successfully recover C. upsaliensis from clinical samples 
(18).  Together, results from this study will facilitate the selection of antibiotics for clinical 
treatment of campylobacteriosis and the formulation of diagnostic media for various 
Campylobacter spp. 
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TABLE 1. Bacterial strains used in this study 
Description Information and phenotype Source or 
reference 
E. coli stains and plasmid 
JM109 Cloning strain for blue and white colony screening Promega 
pGEM-T easy PCR cloning vector, ampr Promega 
 
Campylobacter strains 
700819 C. jejuni NCTC 11168, designated as 700819 by ATCC.  ATCC 
S3b  C. jejuni, isolated from chicken. (50) 
993868 C. coli, isolated from human. Moyer* 
33559 C. coli, isolated from swine. ATCC 
TF1-13 C. coli, isolated from turkey. (24) 
H-8 C. coli, isolated from swine. (24) 
2744 C. upsaliensis, the source of isolation unknown. Wesley ** 
3121 C. lari, isolated from chicken. Wesley 
3125 C. lari, a environmental isolate from sediments. Wesley 
5652 C. fetus, isolated from bovine. Wesley 
6953 C. fetus, isolated from equine. Wesley 
S3b-B S3b derivative; cmeB::cat  This study 
99B 993868 derivative; cmeB::cat This study 
TF99B TF1-13 derivative; cmeB:cat  This study 
44B 2744 derivative; cmeB::cat This study 
21B 3121 derivative; cmeB::cat This study 
25B 3125 derivative; cmeB::cat  This study 
52B 5652 derivative; cmeB::kan  This study 
53B 6953 derivative; cmeB::kan  This study 
* Dr.  Nelson Moyer, University of Iowa. ** Dr. Irene V. Wesley, USDA, ARS, NADC. 
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TABLE 2. PCR and sequencing primers used in this study 
Primers for C. jejuni and C. coli cmeABC 
EFP-1  GGCTTATGAAATTACAGATGCAGA 
ES1  CCCCAATGAAAAATAGGCAG 
cmeC-F1  CGTTGAAGCAAGATGGTA 
ES2 GGCTTCTTTAAGAGCATTTTCA 
cmeC R1 GATGAAAATTTAAATAAAGTGG 
EFP-2 GCTATTGTTTTCTTTTTCCCAAGA 
cmeC_R2 GTGGAATGATGCCAGGATC 
ES3 GTCATTGCTAAATCCCCTTA 
ES4 GCCTATAGTTGCATTCATCG 
EFP-3 TTCTGAGATTGTTCTATGGAGTGC 
ERP-1 CCTGAAGAAGATCAAGGTTTGATG 
ES-5 CGATCCCTATGGCTAAAATT 
MexBR1 AGGAATAAGTGTTGCACGGAAATT 
ES6 CGCCAATTTTACCAGTTGCG 
MexBF1 GGTACAGATCCTGATCAAGCC 
ES7 GGAGGGGTTAAAGAAGGATAT 
ERP-2 AAAAATTCAAGTTGGTAGCGAAGT 
ES8 CGGTTTCTCCATTAAGATTT 
ES9 CGCCACTAACTTGAGGCT 
ERP-3 TCATCTTAATCTTTTAATTAACGCTCC 
ERP-2b  TTGCGACGTAATGAAGGAGA 
 
Primers for C. coli cmeABC 
cmeA4741F  ACTTCGCTACCAACTTGAATTT 
cmeA5346R GCTTGCAAATGCAAGAATTG 
cmeA5769R GCTTTAGGTGTTGTGCTTTTACTC 
cmeC195F  CTCAAATCCTCCACCAAATGCTTT 
cmeC1455R  TCATGGGAAAAAGAAAACAATAGC 
cmeC663F  AGCCGTGCGAGCTACTCC 
coli59-F2  TCAAGCAATGGCTCTATGAAC  
coli86CF1 GGTGGAATGATAGCTGCTTC  
S3b-AF2  GCAAGAGAAGAGTCGTATTCC  
coli86AR1  TGTAGGAGGGGTTAAAGATGG  
coliCF2 TTATCGCGCTTCAAGATCAG  
coliAR2  GCATCAGCTCCTGTGTAAG  
coliCF3 GCAGCTTTTGGAGAAATTCG  
coliAR3  AATCAGCATAGATTGGATTGAG  
coliAR4  CCACGATAACACCGCTTAC  
coliAF1  CGCCATGTTAAGAGAACC 
coliCR1 GGATGGCTTATGGATAAAAC  
cmeRF609 TGGAATCAATAGCTCCAAAG  
cmeCR2  GCGATGAGAAAATTATTACCAG  
(Con't on the next page) 
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TABLE 2. PCR and sequencing primers used in this study (con't from 
prevoius page) 
coliAR4b  AGCACTTAAGAGTAAAAGGG  
coliAR5  GAGAAAATAATTTTGCCAAAGG  
coliCR2  TATCAGGACGCTGCAAGAG 
coliAF2  GGCATAGAAATCATTCGTCCAAG 
coliCR3  AACCCACCTTAAAGTAGAAAA  
coliAF2  GGCATAGAAATCATTCGTCCAAG    
 
Primers for C. upsaliensis cmeABC 
cmeB2654F  CCCAATATGAAAGATGGC  
cmeB3021R GATCATTCCACCAATAAGC  
upsBF1  CGTCCTATTGTGATGACTTC  
upsBR1 GAAAGTCCTATGAGCAGC  
upsBR2 TTTGATTTGCCGCAGCGAC  
upsBF2 ACCGCGATAATTACAATGC  
upsBR3  CGACCAGTCGAAAAAGTC  
upsBR2-2  GCGTTGTTCTAACTCCTG  
upsCF2  ATTAACGCTGCTTTAAGTCG  
upsBR4g  AGAGCAAAAAGGGTAAGC  
upsCF3g CTTATCTTATGGCAAATTCC  
upsBR5g  ACTTCTTTTGAGGTGATTTG  
upsBR6g  TAGCCACACTTTCTGAGATG  
upsBR7g  TTCCCGGAAGCAAAGTGC  
upsBR8g TGCAAGACTTGTATCATACTCC 
upsBF1a TAATGAAATTGATGTTGAGGG 
upsBR9g TGTGCTATTATGGTGCTAACG   
upsBR10 GAAACAAGGATATTGTGAGCG  
upsBF6  TACCGCTATCAACATTGC 
upsCR1  AATGGTATGTGAGCGTAAAG 
upsBF6b  CGCAATGTTGATAGCGGTAA 
 
Primers for C. lari cmeABC 
3121BR1  ACACTATCAAGGGCTACC  
lariBF1  CCTTTTGCTGTTTTTGGTTC  
lariBR1 ATAGCTTGTATAGCCGCATC  
fetusBF1  TGCGCTAACCCTTACTCC  
fetusBR2  CCGATAAGAAGCAAAAGTCC  
lariBF1  CTTTGTGCGGTATTTATCC  
lariBR2 AGCCATCTTTCATATTGAGC  
lariBF3 ACATCTTGGTTGAACAAGC  
lariBF4g  TAGAGCATTTTAAACTCGG  
lariBR2g  AATCTACCTTGCATAGTAACTG  
lariBF5g  ACAGCTTTTGGAGAAATAAG  
lariBR3g GCATCTTCAAGAGGTATAGC  
lariBR4g CAACATTAGCTTGTACTTGG  
(Con't on the next page) 
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TABLE 2. PCR and  sequencing primers used in this study (con't from prevoius 
page) 
lariBR5g  AATCCGTGCTTAATCTTGC  
lariBR6  TCTTCTAAATTCGCATTGG  
lariEF2 AGAGCCTGATAAATATCAAGC  
lariER2 TTCTAATTCATCCATAGAACC  
lariEF3  TGCTATACCTCTTGAAGATGC  
lariER3 CCTGAAATTGTCACAGAAACC  
lariEF4 TAGCATAGCATGGTCAGG  
lariER4 GCTCAGCTTTAAATTTATTAAGC  
lariEF5  AAAAATTCTAGAAGAAACAACC  
lariER5 TTTGTGTGAATAAGAAAGTGC  
lariEF1  TGTGAAATTACAAGGCATTGA 
lariER1  AAATTTGGCTAAACTTGCATC  
 
Primers for C. fetus cmeABC 
6953BR1  GATACTACCGAGTCTAACG  
fetEF1b  CTATAAATGCTTACGCCGTTGA  
fetusBF1  TTCAGTATTTGGCTCACTTC  
fetusBR1  CTACAAAACCTTCCATAAAAG  
fetusBF2g  CTATGGTTGTTGCCACAG  
fetusBR2g  ATTCAGTCGTGTCGTAGCC  
fetusBF3g  GGCCATCTTCAAAGCTAC  
fetusBR3g  ACCACTTGGGTCATAAAACG  
fetusBF4  ATAACGCAAATATATGGAGC  
fetusBR4  TACCGCTTGATATAACTGC  
fetusBF5  TTGATGTGTATAAATCTCTTGG  
fetusBR4b CGTCATTTATACCGCTTG 
fetusBR5 GCTACCCTCGTCAATAACG  
fetusBR6 TCTATAGTTCCTGCTACTTTTG  
fetusR5b TCTCCTTCTTTTACGCTTG  
fetusBR6b  AAGTATTGCGCTTCTTACTG 
fetusBR6b  AAGTATTGCGCTTCTTACTG 
fetEF1  TGAGCCTATAAAACTAAAAGC 
fetER1  TTCATCTATCTGGTATAGTTTA  
fetEF2  TATGCCAGTAACTGTTATGC  
fetER2  ATACACGCTTAGACTCATAG  
fetEF3  CATGGTTCAAGCCAATTAT  
fetER3  GCGCAAATTGTCTTTGTAT  
fetEF4  GTAGAACGGATATTGCATGA  
(Con't on the next page) 
  
TABLE 2. PCR  and sequencing primers used in this study (con't from 
prevoius page) 
fetER4 TGTTGACGCTACTTCTTGAT 
fetEF5  AAGAAGCTTAGGACCAGATA  
fetER5  GGCTTGATAATACGTAAGTT  
fetER6  AACTTAGAGCAAAATGCTAGTT  
fetusBF5  ATCTCTTGGCGGAGGATT  
fetEF1c CACAGTTAAAGTTTCAAGGG 
fetER1b  TTCATCTATCTGGTATAGTTTA  
fetEF6  ACTATGATAGCGCGATGTTA 
fetER6b TTTACTGGCTTGTTTATTGGTC 
 
Degerate primers for cmeB of C. lari and C. fetus 
cmeB1213F  GGDATHGTYGTAGATGATGC  
cmeB2817R GCRAAYTCWACRATYAARATHGCATT  
 
Mutagenesis primers 
chlU ACGGATCCAAAGAGTGACCGCCGAGA  (BamHI)* 
chlL ACTCTAGACAGTGCGACAAACTGGGA (XbaI) 
kanU ATGGATCCTGCAAGGAACAGTGAAT (BamHI) 
kanL ATTCTAGAGCGATGAAGTGCGTAAG (XbaI) 
99UBF CAATCCGTTAGTACAATGAG  
99UBR ACGGATCCCATATTATCTGCGCCATTGA (BamHI) 
99LBF GGTCTAGAGGAGTGGATCAGCTTATCAA (XbaI) 
99LBR GTATTCTCCTACTGCTCCTA  
LarUF TCTAGCTTGTGCTTCGCTTA  
LarUR  TTGGATCCGAAGAGCTTGAGGTTGAATC (BamHI) 
LarLF  AATCTAGAGGCCATTGGTATTGTGGTTG  (XbaI) 
LarLR  GTGCAGGATCACCTTGAACT  
FetUF  TATGCCAGTAACTGTTATGC  
FetUR  ACGGATCCTAGTATCGGCTATAGTCTGT (BamHI) 
FetLF  ACTCTAGATGTTCGCACTTATACTAGCC   (XbaI) 
FetLR  TGATACTACCGAGTCTAACG  
44BUF  CAGCTTGTAAGCGATTATGA  
44BUR  ACGGATCCAGCGATAACTTCTAGTATGC (BamHI)  
44BLF  ACTCTAGAAGCTAGTATGGCTCTAATCG   (XbaI) 
44BLR  CTAAGGTAGAAGCAGCTATC  
* Restriction sites are underlined and labeled in parehtheses. 
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Table 3.1. Pairwise amino acid sequence homology of CmeA among the Campylobacter spp. 
C. jejuni C. coli C. upsaliensis C. lari C. fetus    Campylobacter strains 
11168 81176  RM1221 S3b 33559 TF1-13 993868 H8 2744 3121 3125 5652 6953 
11168   98 100 100 81 80 86 86 64 56 56 44 44 
81176    99 99 81 80 85 85 64 55 55 43 43 
RM1221     100 81 80 86 86 64 55 55 44 44 
C. jejuni 
S3b         81 80 86 86 64 55 55 44 44 
33559           100 95 94 66 58 58 44 44 
TF1-13          94 95 66 58 58 44 44 
993868           100 66 57 57 43 43 
C. coli 
H8                 66 57 57 43 43 
C. upsaliensis 2744                  59 58 43 43 
3121                     99 43 43 C. lari 
3125                       43 43 
5652                         100 C. fetus 
6953                           
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  Table 3.2. Pairwise amino acid sequence homology of CmeB among the Campylobacter spp. 
C. jejuni C. coli C. upsaliensis C. lari C. fetus  Campylobacter strains 
11168 81176 RM1221 S3b 33559 H8 TF1-13 993868 2744 3121 3125 5652 6953 
11168   99 99 99 93 94 96 98 76 74 74 60 60 
81176    100 100 93 95 96 98 76 75 75 60 60 
RM1221     100 93 95 96 98 76 74 74 60 60 
C. jejuni 
S3b         93 95 96 98 76 74 74 60 60 
33559           93 93 93 76 74 74 60 60 
H8          96 97 76 75 75 60 60 
TF1-13           98 77 74 74 61 61 
C. coli 
993868                 76 75 75 60 60 
C. upsaliensis 2744                   73 73 59 59 
3121                     100 61 61 C. lari 
3125                       61 61 
5652                         100 C. fetus 
6953                           
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 TABLE 3.3   Pairwise amino acid sequence homology of CmeC among the Campylobacter spp. 
C. jejuni C. coli C. upsaliensis C. lari C. fetus 
Campylobacter 
11168 81176 RM1221 S3b 33559 H8 993868 TF1-13 2744 3121 3125 5652 6953 
11168   100 99 99 85 86 85 85 60 54 54 35 35 
81176    99 99 85 86 85 85 60 54 54 35 35 
RM1221     100 85 86 85 85 60 55 55 35 35 
C. jejuni 
S3b         85 86 85 85 60 55 55 35 35 
33559           100 100 100 57 52 52 35 35 
H8          100 100 57 52 52 35 35 
993868           100 57 52 52 35 35 
C. coli 
TF1-13                 57 52 52 35 35 
C. upsaliensis 2744                   58 58 36 36 
3121                     100 37 37 
C. lari 
3125                       37 37 
5652                         100 
C. fetus 
6953                           
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 TABLE 3.4   Pairwise amino acid sequence homology of CmeR among the Campylobacter spp. 
C. jejuni C. coli C. upsaliensis C. lari C. fetus 
Campylobacter 
11168 81176 RM1221 S3b 33559 993868 H8 TF1-13 2744 3121 3125 6953 
11168   100 99 98 71 71 71 71 64 37 37 29 
81176    98 98 72 72 72 72 64 37 37 29 
RM1221     100 71 71 71 71 64 37 37 30 
C. jejuni 
S3b         71 71 71 71 64 37 37 30 
33559           100 100 100 59 34 34 31 
993868          100 100 59 34 34 31 
H8           100 59 34 34 31 
C. coli 
TF1-13                 59 34 34 31 
C. upsaliensis 2744                   39 39 29 
3121                     100 28 C. lari 
3125                       28 
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TABLE 4.1.  MIC test results of Campylobacter wild-type and isogenic CmeB mutant strains 
C. jejuni 700819 C. jejuni  S3B C. coli  993868 C. coli  TF1-13 Campylobacter strains 
WT* B-**   WT B-   WT B-   WT B-   
Ciprofloxacin 0.25 0.0313 (8) 0.5 0.0625 (8) 0.25 0.0313 (8) 0.25 0.0313 (8) 
Erythromycin 1 0.063 (16) 1 0.031 (32) 1 0.031 (32) 256 4 (64) 
Ampicillin 8 2 (4) 16 1 (16) 256 128 (2) 16 8 (2) 
Cephalothin 256 8 (32) 256 4 (64) 2048 32 (64) 2048 8 (256) 
Cefoperazone 256 16 (16) 1024 16 (64) 2048 128 (16) 1024 32 (32) 
Cefotaxime 8 0.0625 (128) 16 0.0625 (256) 16 0.25 (64) 16 0.0625 (256) 
Gentamicin 2 1 (2) 2 1 (2) 1 0.5 (2) 1 0.5 (2) 
Ethidium bromide 1 0.125 (8) 0.5 0.0625 (8) 8 0.5 (16) 4 0.25 (16) 
Polymyxin B 8 4 (2) 4 2 (2) 2 4 (1) 2 4 (1) 
Tetracycline 0.13 0.06 (2) 64 8 (8) 0.5 0.13 (4) 128 8 (16) 
Rifampin 256 1 (256) 256 0.5 (512) 64 0.0625 (1024) 128 0.25 (512) 
Cholic acid 8192 128 (64) 8192 128 (64) 4096 256 (16) 8192 256 (32) 
SDS 16 4 (4) 32 4 (8) 16 4 (4) 32 8 (4) 
* Wild type strain.  ** The CmeB mutant.  The MIC values are in μg/ml. Numbers in parenthesis are the fold changes between the wild type and CmeB 
mutant. 
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 TABLE 4.2 MIC test results of Campylobacter wild-type and isogenic CmeB mutant strains 
C. upsaliensis  2744 C. lari  3121 C. fetus  5652 Campylobacter strains 
WT* B-**   WT B-   WT B-   
Ciprofloxacin 0.5 0.063 (8) 32 2 (16) 1 0.063 (16) 
Erythromycin 0.125 0.0078 (16) 2 0.0313 (64) 1 0.25 (4) 
Ampicillin 1 0.25 (4) 2 0.125 (16) 8 0.25 (32) 
Cephalothin 2 0.25 (8) 128 0.5 (256) 16 0.0625 (256) 
Cefoperazone 16 0.0625 (256) 256 0.125 (2048) 256 0.125 (2048) 
Cefotaxime 1 0.0625 (16) 32 0.0625 (512) 8 0.015625 (512) 
Gentamicin 8 8 (1) 16 16 (1) 32 32 (1) 
Ethidium bromide 8 0.25 (32) 4 1 (4) 16 1 (16) 
Polymyxin B 2 4 (0.5) 4 8 (0.5) >512 >512 - 
Tetracycline 1 0.125 (8) 8 0.5 (16) 8 0.5 (16) 
Rifampin 8 0.0625 (128) 64 0.5 (128) 128 128 (1) 
Cholic acid 2048 32 (64) 8192 32 (256) 8192 128 (64) 
SDS 64 8 (8) 256 8 (32) 256 16 (16) 
* Wild type strain   ** The CmeB mutant. The MIC values are in μg/ml. Numbers in parenthesis are the fold changes between the 
wild type and CmeB mutant.  
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FIG. 1. Genomic organization of the cmeABC operon in Campylobacter spp. Boxed arrows depict 
individual ORFs and the name of each ORF is labeled on top of the diagram. The letters J, C, U, 
L and F stand for C. jejuni, C. coli, C. upsaliensis, C. lari, and C. fetus, respectively. IR stands for 
intergenic region between cmeR and CmeABC. 
J 
C 
U 
L 
F 
cmeR      IR cmeA cmeB       6cmeC cj0364  cj03 3c 
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FIG. 2. Dendrograms constructed from the amino acid sequence alignments of CmeA (Panel A), 
CmeB (Panel B) and CmeC (Panel C) in different Campylobacter spp. The labels Cj, Cc, Cu, Cl 
and Cf stand for C. jejuni, C. coli, C. upsaleinsis, C. lari, and C. fetus, respectively. The name of 
each strain is labeled in the parenthesis immediately following the species name. The number in 
the parenthesis following the strain’s name indicates the levels of diversity. 
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B 
C 
   1   2   3   4    5    6   7    
 CmeA (38Kd)  
   1   2   3   4    5    6   7    
CmeB (120Kd) 
   1   2   3   4    5    6   7    
CmeC (53Kd)  
FIG. 3.  Immunoblotting analysis of the CmeABC proteins using antibodies made from 
recombinant proteins of CmeA, CmeB, and CmeC of C. jejuni 81-176. Bacterial membrane 
fractions of C. jejuni (Lane 2), C. coli (Lanes 3 and 4), C. upsaliensis (Lane 5), and C. lari 
(Lanes 6 and 7) were separated by SDS-PAGE, transferred to nitrocellulose membranes, 
and blotted with anti-CmeA (A), anti-CmeB (B), and anti-CmeC antibodies, respectively. 
Lane 1 contains prestained protein ladder. 
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Abstract 
 
    CmeR, the local repressor of efflux pump CmeABC, was recently identified as a 
pleiotropic regulatory protein in C. jejuni by using microarray and RT-PCR. Among the 
genes up-regulated in the CmeR mutant are cj0035c and cj0561c, which are predicted to be 
an efflux pump of the major facilitator system (MFS) family and a putative periplasmic 
protein, respectively. In this study, gel electrophoretic motility assay and promoter fusion 
assay revealed that CmeR as a repressor, directly regulates cj0035c and cj0561c. 
Transcriptional fusion assay indicated that both Cj0035c and Cj0561c were expressed 
constitutively at low levels and their expression levels were inducible by bile salts and other 
detergents in a similar manner as in cmeABC. MIC tests suggested that Cj0561c plays a 
moderate role in antibiotic resistance in the presence of cholic acid, but the role of Cj0035c 
in antibiotic resistance was not detected. Sensitivity tests on heavy metals showed the MIC of 
mercury and cadmium were reduced by 2- to 4-fold, respectively, in the Cj0561c mutant, but 
no change was observed with the Cj0035c mutant. Mixed infection of chickens with the 
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cj0561c mutant and the wild-type strain revealed that the Cj0561c mutant was significantly 
less competitive in the colonization of chicken ceca, indicating that Cj0561c is regulated for 
the adaptation of C. jejuni in the intestinal tract. 
 
Introduction 
 
    Multidrug resistance (MDR) efflux pumps are membrane transport proteins identified in 
both eukaryotic and prokaryotic cells and are responsible for the extrusion of structurally 
dissimilar antibiotics and other toxic compounds inside cells (10, 28, 29).  Based on the 
similarity of structure and energy source, MDR efflux pumps are classified into five major 
families: resistance-nodulation-division (RND), the major facilitator superfamily (MFS), 
multidrug and toxic compound extrusion (MATE), small multidrug resistance (SMR), and 
ATP binding cassette (ABC) (29, 34). Except for the ABC family, which utilizes the energy 
from ATP hydrolysis, all of the other families of efflux pumps utilize proton motive force as 
the energy source (22, 23). Analysis of prokaryotic genomes indicates that the numbers of 
efflux transporters encoded in an organism are proportional to its genome size and often 
multiple efflux systems exist in one organism (24, 25). Generally, the majority of MDR 
efflux pumps identified and experimentally characterized in Gram-negative bacteria fall into 
the RND family, which is composed of an inner membrane transporter, an outer membrane 
channel protein and a periplasmic fusion protein (25, 29). Bacterial MDR efflux pumps are 
often under the control of regulatory proteins and associated with the intrinsic and acquired 
resistance to antibiotics and other toxic compounds (5, 31, 32). Elevated expression of MDR 
efflux pumps can result in a MDR phenotype in bacteria (6-8). Although most of the MDR 
efflux pumps are discovered due to the multidrug resistance phenotype, MDR efflux pumps 
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may also play important roles in bacterial physiology (27). The natural functions (other than 
antibiotic resistance) of bacterial MDR efflux pumps are generally unknown and represent a 
major effort in the study of bacterial efflux transporters. The expression of MDR efflux 
pumps can be under the control of local regulators, two-component systems, or global 
regulatory proteins (6, 7, 27). The local regulators of MDR efflux systems usually have the 
helix-turn-helix DNA-binding motifs, and are classified into different families depending on 
the sequence homology, three dimensional structure and function (8). Local regulators can be 
repressors or activators for the MDR efflux pump.  
 
    C. jejuni is a microaerophilic, thermophilic and fastidious Gram-negative bacterium and is 
a major foodborne pathogen (19). Human infections by C. jejuni are mainly characterized as 
gastroenteritis, but can be manifested as other clinical diseases, such as bacteremia, abortion, 
renal and urinary infections, etc. Severe clinical sequelae, such as Guillain-Barré syndrome 
(GBS) and reactive arthritis, may also occur following Campylobacter infections (19). 
Clinically, human campylobacteriosis is often self-limiting, but antibiotic treatment is needed 
in severe cases or in immunocompromised patients (2). However, antibiotic resistant 
Campylobacter have increased rapidly in the past 15 years worldwide (20). One of the major 
mechanisms involved in antibiotic resistance is the drug efflux system. Genomic sequence 
analysis showed that there are 13 putative efflux pumps: 1 ABC, 2 RND, 4 MFS, 2 MATE 
and 4 SMR family efflux pumps in C. jejuni (13). CmeABC is a RND family efflux 
transporter which plays a significant role in antibiotic resistance in Campylobacter. This 
efflux system is also involved in bile resistance and in vivo colonization in chickens (4, 15, 
16).  
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    It has been demonstrated that CmeABC is controlled by a repressor named CmeR, which 
belongs to the TetR family of regulator proteins (12, 14). The TetR family consists of a large 
number of regulatory proteins involved in the regulation of efflux transporters, antibiotic 
resistance and other physiological functions (32). CmeR serves as a repressor for CmeABC 
through the direct binding of its helix-turn-helix (HTH) domain to an inverted repeat 
sequence in the promoter region of cmeABC (12, 14). As identified in other bacteria, such as 
AcrR for AcrAB in E. coli (36), mutations in the binding site or CmeR can result in the 
overexpression of the CmeABC efflux pump and a MDR phenotype (12, 14). Transcriptional 
profiling of the CmeR null mutant by DNA microarray demonstrated that CmeR modulates 
the expressions of multiple genes of diverse functions in C. jejuni (37). Among the genes up-
regulated by CmeR were cmeABC, cj0035c and cj0561c. The upregulation of these genes by 
CmeR was further confirmed by real-time RT-PCR (37). According to sequence homology, 
Cj0035c is a putative MFS transporter and Cj0561c is a possible periplasmic protein (21), but 
the regulatory mechanisms and functions of the two gene products are unknown.  The fact 
that Cj0035c and Cj0561c are predicted membrane-associated transporter proteins and both 
are regulated by CmeR suggests that Cj0035c and Cj0561c may be involved in antibiotic 
resistance or other physiological process in C. jejuni.  In this study, we characterized the 
regulation of Cj0035c and Cj0561c by CmeR and initiated the work to determine the 
functions of two proteins in C. jejuni. 
 
Materials and Methods 
 
    Bacterial strains and culture conditions.  Bacterial strains and plasmids used in this 
study were listed in Table 1. C. jejuni 11168 purchased from American Type Culture 
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Collection (ATCC) was grown in Mueller-Hinton (MH) broth (Difco, BD) at 42°C overnight 
in a sealed jar filled with gas mixture of 5% O2, 10% CO2 and 85% N2. E. coli was grown in 
Luria-Bertani (LB) broth (Difco, BD) at 37°C overnight on a shaker at 200 rpm. For the 
selection and growth of C. jejuni and E. coli mutants, MH and LB media were supplemented 
with 30 μg/ml of kanamycin, 4 or 20 μg/ml of chloramphenicol, or 100 μg/ml of ampicillin.  
 
    Construction of isogenic mutants. Coding regions of cj0035c and cj0561c were 
amplified by the Taq poylomerase (Promega) with primer pairs of cj0035cFU/cj0035cFL and 
cj0035cRU/cj0035cRL, 561UF/561UR, and 561LF/561LR (Table 2), respectively. A 
chloramphenicol resistance cassette (cat) was amplified by the Pfu polymerase (Stratagene) 
from the pOUA18 plasmid using primers chlU and chlL (Table 2). The amplified DNA of 
cj0035c and cj0561c and the cat cassette were digested with the restriction enzymes and 
purified by the PCR clean-up kit (Promega). The purified DNA of cj0035c and cj0561c was 
separately ligated to the cat cassette by T4 DNA ligase (Promega) and the ligated DNA with 
the cat cassette flanked by the internal regions of cj0035c or cj0561c was purified by 0.8% 
agarose gel electrophoresis. The purified cj0035c or cj0561c DNA with the inserted cat 
cassette was ligated to the pGEM-T vector (Promega) by T4 DNA ligase and the ligation 
mixture was transformed to E. coli JM109 competent cells. Transformants were selected on 
LB plates supplemented with ampicillin and chloramphenicol. The pGEM-T plasmids 
carrying the cat cassette flanked by either cj0561c or cj0035c DNA were extracted from E. 
coli and introduced into C. jejuni 11168 via electroporation. cj0561c and cj0035c mutants 
were selected on MH agar plates with 4 μg/ml of chloramphenicol and the double-crossover 
in each mutant was confirmed by PCR.  
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    To make double mutants of cmeB /cj0561c and cmeB/cj0035c, C. jejuni 11168 cmeB 
mutant (kanr) genomic DNA was introduced into the cj0561c and cj0035c mutants by natural 
transformation (1). Double mutants were selected by plating on MH agar plate with both 
chloramphenicol and kanamycin. The double mutations in each mutant were confirmed by 
PCR. 
 
    Construction of transcriptional lacZ fusions. The promoter regions of cj0035c and 
cj0561c were amplified from C. jejuni 11168 genomic DNA by the Pfu polymerase with the 
primer pairs 0035PF/0035PR and 561PF/561PR, respectively (Table 2). The PCR amplified 
DNA was digested using BamHI and XbaI and ligated to the pMW10 plasmid linearized with 
the same restriction enzymes. The multicloning site on the pMW10 is located upstream of a 
promoterless lacZ gene, such that the inserts will be fused with the promoterless lacZ gene. 
The ligation mixtures were transformed to competent E. coli DH5α cells. Colonies with 
desired plasmid constructs were selected on LB agar plates with kanamycin. PCR and DNA 
sequencing were performed to verify there were no mutations in the inserted promoter DNA. 
The constructed promoter-lacZ fusion plasmids were transferred to C. jejuni 11168 using the 
triparental conjugation method reported previously (18).   
     
    ß-galactosidase assay and induction of cj0035c and cj0561c. Promoter activities of 
cj0035c and cj0561c were measured in W7 and its isogenic CmeR mutant using pMW0035 
and pMW0561. The ß-galactosisase assay were performed as described previously (12, 17).  
 
    For the induction assay, C. jejuni W7 and the isogenic cmeR mutant carrying pMW0035 
and PMW0561 were grown under microaerobic conditions in MH broth or MH broth 
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supplemented with cholic acid (2.0 mg/ml), taurocholic acid (4.0 mg/ml), and SDS (25 
μg/ml) for 16 hr.  ß-galactosidase assays were conducted as described above.  
 
 
    Gel electrophoretic mobility shift assay (EMSA). Promoter regions of cj0561c and 
cj0035c were amplified by the Taq polymerase with the primer pairs cj0035uF1/cj0035uR1 
and cj0561uF1/cj0561uR1, respectively (Table 2), purified, and labeled using the 3'-end 
DIG-labeling Kit (Roche). EMSA was performed as described previously (12). Briefly, 20 to 
200 ng of CmeR and  0.2 pmol of DIG-labeled promoter DNA were mixed in a final volume 
of 20 μl in 1× binding buffer containing 20 mM HEPES (pH 7.6), 1mM EDTA, 10 mM 
(NH4)SO4, 5 mM dithiothretol (DTT), 0.2% Tween 20, 30 mM KCl and 25 ng poly(ddI-dC). 
The mixture was incubated at room temperature for 15 min, mixed with sample buffer and 
loaded onto 6% non-denatured polyacrylamide gel in 0.25 × TBE (pH 8.0). The 
electrophoresis was performed in 0.25 × TBE (pH 8.0) at 200 volts for 45 min and the 
separated samples were transferred to positively charged nylon membrane using a vacuum 
blotter at 65 mbar for 1 h. DNA was cross-linked to the nylon membrane by a UV crosslinker 
and the membrane was blocked by the Block Solutions (Roche, cat no. 1 585 762). The 
membrane was stained with 1:10,000 diluted alkaline phosphatase labeled anti-DIG antibody 
and was detected using the CDP-Star reagent (Roche).  
 
    Overexpression of Cj0561c. The cmeABC promoter and the entire cj0561c ORF plus its 
cognate ribosomal binding site were amplified by primer pairs BSF1/AR2 and 
0561Fc/0561Rc (Table 2), respectively. The PCR products of the cmeABC promoter and 
cj0561c ORF were treated with BamHI/XbaI and XbaI/SacI, respectively, and then ligated to 
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pRY108 treated with BamHI/SacI, resulting in plasmid pRY-abc-Cj0561c, in which the 
cj0561c was under the control of the cmeABC promoter. The constructed plasmid was 
introduced into W7 by triparental conjugation as describe above (18). 
 
    Production of recombinant proteins and preparation of polyclonal antibodies of 
Cj0561c. The pQE 30 plasmid (Qiagen) was used to express his-tagged recombinant protein 
of Cj0561c. Briefly, a portion of Cj0561c coding sequences was amplified by the Pfu 
polymerase with primers 561clF and 561clR listed in Table 2. The PCR products were 
digested with the corresponding restriction enzymes and ligated to the pQE30 plasmid 
digested with the same restriction enzymes. The recombinant plasmids were electroporated 
into E. coli M15 (pRep4, kanr, Qiagen). Transformants were selected on LB plates containing 
30 μg/ml of kanamycin and 100 μg/ml of ampicillin. Representative colonies were selected 
and plasmids were sequenced to confirm there were no mutations in the protein coding 
sequences. The recombinant proteins were purified using the Ni-NTA column (Qiagen) 
following the manufacturer’s instructions.  
 
    Preparations of whole cell proteins, cellular and periplasmic fractions. Whole cell 
proteins were prepared as described previously with 24 hr MH culture (15). Periplasmic and 
spheroplasmic fractions were prepared by using the PeriPreps (Epicentre) following the 
manufacturer’s instruction. Briefly, a 24 hr Campylobacter culture was harvested by low-
speed centrifugation (3,000 × g, 10 min) and resuspended in 50 μl of PeriPreps Periplasting 
Buffer and incubated (room temperature for 5 min). Then 50 µl of purified water cooled at 4 
°C was added and the mixture was incubated on ice for 5 min. The mixture was subject to 
centrifugation in a bench-top centrifuge (17,000 × g, 2 min) at room temperature. The 
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supernatant was collected as periplasmic preparation. The pellet was resuspended in 100 μl 
of 10 mM HEPES buffer and sonicated with 10 bursts of 10 sec each with 10 sec intermittent 
at setting 8.0 on ice. Sonicated samples were centrifuged (100,000 × g for 2 hr at 4 °C), and 
supernatant and pellet were collected as intracellular and membrane fractions, respectively.  
 
    SDS-PAGE and Western blotting analysis. Whole cell proteins, membrane and cellular 
proteins were separated on 10% SDS-PAGE at 100 V for 15 min and then 200 V for 60 min, 
transferred to nitrocellulose membrane at 80 V for 60 min. The nitrocellulose membrane was 
blocked with blocking buffer (5% skimmed milk in PBS with 0.02% Tween 20), and then 
incubated with 1:500 diluted anti-Cj0561c polyclonal antibodies in blocking buffer at room 
temperature for 1 hr. After three washes in PBS with 0.02% Tween 20 (10 min per wash), the 
membrane was incubated with 1:1,000 diluted horseradish peroxidase-labeled goat-anti-
rabbit IgG (KPL) in the blocking buffer. After washing, the membrane was developed using 
the 4-CN substrate system (KPL).  
 
    Minimal inhibitory concentration (MIC) of antibiotics and toxic chemicals. C. jejuni 
W7 and its mutants were tested for MICs of antibiotics and toxic chemicals using a standard  
microdilution method (9). Serial dilutions of antibiotics and chemicals were made in 50 μl of 
MH broth in 96-well plates and 50 μl of fresh bacterial culture containing 1×106 CFU/ml 
cells were added to each well and incubated (42 °C for 48 h) microaerobically.  Antibiotics 
and chemicals tested include ciprofloxacin, erythromycin, ampicillin, cephalothin, 
cefoperazone, cefotaxime, gentamicin, ethidium bromide, polymyxin B, vancomycin, 
tetracycline, rifampin, cholic acid, and SDS. Heavy metals include CdCl, HgCl2, CuSO4, 
ZnCl2, NiCl, MnCl2, and CoCl. 
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    Chicken study. One-day old broilers were purchased from a commercial hatchery. The 
birds were housed in the Laboratory Animal Resource facilities at the Iowa State University, 
and feed and water were provided ad libitum throughout the experiments. For chicken 
colonization study, 45 birds were randomly separated into three groups of 15 birds. Each 
group was inoculated separately on day 3 with 0.1 ml of culture containing approximately 
104 (Experiment 1) or 106 (Experiment 2) CFU of bacterial cells of W7, the cj0035c mutant 
or the cj0561c mutant. Following the inoculation, 5 birds from each group were euthanized 
by CO2 and cecal contents were collected on days 3, 6, and 9 post inoculation. Cecal contents 
from each bird was weighed and diluted in MH broth. The diluted samples were plated onto 
MH agar plates with Campylobacter selective supplements. The CFU count per gram of fecal 
samples was calculated and used for statistical analysis.   
 
    For the mixed competition study between W7 and the cj0561c mutant, 12 birds were orally 
inoculated on day 3 with 0.1 ml mixture of bacterial culture containing 5×106 CFU/ml of 
both C. jejuni W7 and the cj0561c mutant in an approximately 1:1 ratio as measured by 
OD600. The inoculated birds were sampled by cloacal swabs on day 3 and 6 post inoculation. 
The rest of the birds were euthanized on day 9 post inoculation and cecal samples were 
collected.  The fecal samples from cloacal swabs and cecal contents were diluted with MH 
broth and plated on MH agar plates with Campylobacter Selective Supplements (Oxiod). 
Chloramphenicol (4 μg/ml) was added to the MH agar plates to recover the cj0561c mutant 
from fecal samples. The selective medium for cj0561c mutant has been tested so that it 
allows the recovery of cj0561c mutant while eliminating W7. The colony forming units per 
gram of fecal samples were calculated and analyzed by one-way ANOVA.  
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Results 
 
    Genomic and sequence features cj0035c and cj0561c.  Cj0035c and Cj0561c are 
predicted to be a major facilitator family transporter and a periplasmic protein, respectively. 
In the genome of C. jejuni 11168, cj0561c stands alone, but cj0035c forms a putative operon 
with the downstream gene cj0034c. cj0034c and cj0035c overlap by 4 nucleotides and only a 
single RpoD promoter was predicted upstream of cj0035c by a Hidden Markov Model 
(HMM) (26). There was a 153 bp intergenic region between cj0561c and the upstream gene 
dnaB. Two sets of inverted repeats of TGTAAT, which are similar to the one located in the 
cmeABC promoter region, were identified in the promoter region of cj0561c, which may 
serves as the binding site(s) for CmeR. Transmembrane domain prediction by TMHMM 
Server v. 2.0 (http://www.cbs.dtu.dk/services/TMHMM/) indicated that Cj0035c carries 12 
transmembrane helices, which is a typical feature of the MFS efflux pumps. Cj0561c does 
not have transmembrane helix as revealed by the TMHMM Server v. 2.0. But a 20-amino 
acid signal peptide sequence was identified at the N-teriminal of Cj0561c, indicating that the 
protein is secreted. BLAST search indicated Cj0561c is highly conserved among different 
strains of C. jejuni and homologs of Cj0561c were also identified in C. coli, but absent in 
other Campylobacter spp. Interestingly, homologs of Cj0561c are also present in 
Helicobacter hepaticus, Vibrio splendidus and Vibrio fischeri with a sequence identity of 
34%, 26%, and 26%,  respectively, to Cj0561c in C. jejuni 11168. Different from Cj0561c, 
homologs of Cj0035c are identified in most of the sequenced Campylobacter spp. The 
sequence homology of Cj0035c compared with C. jejuni 11168 are 99% in C. coli, 78% in C. 
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upsalienesis, 62% in C. lari, 45% in Wolinella succinogenes, 36% in Pseudomonas 
aeruginosa, and 36% in Pseudomonas fluorescens. 
 
    Transcriptional fusion assay confirmed that cj0035c and cj0561c are subject to the 
regulation by CmeR. In a previous study using DNA microarray and RT-PCR, cj0035c, 
cj0561c, and cj0366c (cmeB) were up-regulated in the CmeR mutant, suggesting that CmeR 
serves as a repressor for multiple genes (37). To confirm this regulation, the promoter regions 
of cj0035c and cj0561c were fused with the promoterless lacZ gene on the pMW10 plasmid. 
The constructed pMW10 plasmids with cj0035c and cj0561c promoters were introduced into 
C. jejuni 11168 and its isogenic CmeR mutant.  As shown in Fig. 1, the promoter activities of 
cj0035c and cj0561c increased 3.4- and 46-fold, respectively, in the cmeR mutant (W7R) 
background. These results are consistent with the finding from the DNA microarray and 
further confirm that CmeR represses cj0035c and cj0561c (37).  
 
    CmeR regulates cj0035c and cj0561c directly. To further elucidate if CmeR regulates 
cj0035c and cj0561c directly or indirectly, EMSA was performed with DIG-labeled DNA of 
the promoter regions of cj0035c and cj0561c. As shown in Fig. 2, the DNA-CmeR complex 
was detected with DIG-labeled cj0035c or cj0561c promoter DNA probes, but was absent in 
the control DNA probe. This finding is a strong indication that CmeR can bind directly to the 
promoter regions of cj0035c and cj0561c and serves as a regulator for the two genes.  
 
    cj0561c and cj0035c genes are inducible by bile salts and detergents. Our previous 
studies have shown that bile salts are inducers of CmeR (14). Since CmeR regulates cj0035c 
and cj0561c, it is possible that bile salts also induce the expression of cj0035c and cj0561c. 
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This possibility was investigated using transcriptional fusion assays. As shown in Fig. 3, the 
promoter activity of cj0035c increased by 3.4-, 4.4-, and 2.6-fold, and the promoter activity 
of cj0561c increased 17-, 28-, and 4.7-fold, respectively, in the presence of cholic acid, 
taurocholic acid, and SDS. The patterns of the inductions of cj0035c and cj0561c by bile 
salts were similar to that of cmeABC reported in a previous study (14), in which taurocholic 
acid is a stronger inducer than cholic acid. 
 
    Localization of Cj0561c in C. jejuni. Recombinant protein of Cj0561c was expressed in 
E. coli and purified using Qiagen Ni-NTA beads. Polyclonal antibodies against Cj0561c were 
raised in a New Zealand rabbit. Different cellular fractions from W7 whole cells were 
analyzed by Western blotting with the Cj0561c antibody. As shown in Fig. 4, Cj0561c was 
identified in the membrane fraction with a MW of 30 Kd, suggesting that Cj0561c as a 
predicted periplasmic protein is physically attached to a membrane protein. 
 
    Functions of Cj0035c and Cj0561c. To characterize the functions of Cj0035c and 
Cj0561c, the two genes were interrupted by the insertion of a cat cassette through 
homologous recombination. The insertional mutations in cj0035c and cj0561c were 
confirmed by PCR. MIC tests were conducted with the wild-type strain and the cj0035c and 
cj0561c mutants with varoius antibiotics, toxic compounds and heavy metals. No changes in 
MICs were observed in either of the mutants with ciprofloxacin, erythromycin, ampicillin, 
cephalothin, cefoperazone, cefotaxime, gentamicin, ethidium bromide, polymyxin B, 
vancomycin, tetracycline, rifampin, cholic acid, SDS, CuSO4, ZnCl2, NiCl, MnCl2, and 
CoCl. However, 2- and 4-fold decrease was observed in the MICs of HgCl and CdCl2, 
respectively, in the cj0561c mutant (Table 3).  
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    The lack of MIC change in the cj0035c and cj0561c mutants may be due to the low 
baseline expression of the two genes. Since cj0035c and cj0561c can be induced by bile salts 
which are normally present in the intestinal tract, we hypothesized that Cj0035c and Cj0561c 
might play a noticeable role in antibiotic resistance in vivo. Therefore MIC tests were 
conducted in the presence of cholic acid as an inducer for cj0035c and cj0561c. As shown in 
Table 3, the resistance of the cj0561c mutant in the presence of cholic acid to tetracycline, 
erythromycin, rifampin and SDS decreased by 2- to 4-fold compared with the wild type 
strain. But there were no changes observed in MIC for the cj0035c mutant in the presence of 
cholic acid. This finding suggested that Cj0561c plays a moderate, but measurable role in 
antibiotic resistance when overexpressed in the presence of bile salts in vivo. 
 
    In addition, Cj0561c was overexpressed in C. jejuni using a shuttle plasmid in which 
cj0561c was under the control of the promoter of cmeABC. Western blotting analysis of the 
Cj0561c protein confirmed the overexpression of Cj0561c in the C. jejuni 11168 clone 
carrying plasmid pRY-abc-Cj0561c (Fig 5). MIC tests with various antibiotics did not reveal 
any change with the construct (data not shown), indicating that the overexpression of 
Cj0561c alone did not confer increased resistance to antibiotics.  
 
    Mutation in Cj0561c reduces the fitness of C. jejuni in chicken ceca.  Chicken 
colonization was performed with C. jejuni W7 and its isogenic mutants of Cj0035c and 
Cj0561c. The chickens were colonized extensively and no differences were observed among 
the groups inoculated individually with W7 and its isogenic mutants of Cj0035c and 
Cj0561c. The colonization experiment was repeated again and similar results were obtained, 
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indicating that when inoculated separately from the wild-type strains, the mutants did not 
show a significant change in colonization (Fig. 6). However, in the group of chickens 
inoculated with a mixture of W7 and the Cj0516c mutant, significant differences (P<0.0001) 
in the levels of colonization were observed between W7 and Cj0561c mutant on days 3, 6 
and 9 post inoculation (Fig 6). This result revealed that the Cj0561c mutant was less 
competitive than the wild-type strain when co-inoculated into chickens, indicating that 
Cj0561c contributes to the adaptation of Campylobacter in the intestinal tract. 
 
Discussion 
 
    CmeR, initially recognized as a local regulator for CmeABC (12), was later identified as a 
pleiotropic regulator by DNA microarray and real-time PCR (37). In this study, the 
regulation of cj0035c and cj0561c by CmeR was further confirmed by promoter fusion 
assays. Promoter fusion assays indicated that cj0035c and cj0561c were expressed in MH 
broth culture at low levels, but bile salts and other detergents can induce higher-level 
expressions of cj0035c and cj0561c. EMSA showed that CmeR directly regulates the 
expression of cj0035c and cj0561c through binding to the promoter regions of the two genes. 
These findings indicated that Cj0035c and Cj0561c are regulated by CmeR in a way similar 
to cmeABC. Insertional mutagenesis of cj0035c and cj0561c showed that Cj0561c, but not 
Cj0035c, was associated with the resistance to cadmium and mercury. Furthermore, when 
induced by bile salts, Cj0561c contributes moderately to antimicrobial resistance in C. jejuni. 
However, no role of Cj0035c in antibiotic resistance was detected in this study. 
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    In a previous study by our laboratory, an inverted repeat, TGTAATaaatATTACA, was 
identified in the promoter region of cmeABC which serves as the binding site for CmeR (12). 
Promoter sequence analysis of cj0035c and cj0561c showed that there were two sets of 
inverted repeats (TGTAATattaGTTACA and TGTAATttaATTACA) in the promoter region 
of cj0561c, but the inverted repeat (AAGATTGActcgttaaaaTCATTCTT) identified in the 
cj0035c promoter region is atypical and different from the ones present in the promoter 
regions of cj0561c and cmeABC. These findings suggest that CmeR is flexible in the 
recognition and binding of target promoter DNA sequences in C. jejuni. Comparison of the 
promoter activities of cj0035c and cj0561c with that of cmeABC reported in a previous study 
(12) suggests that CmeR has a tighter control on cj0561c than on cmeABC. This phenomenon 
may be explained by the fact that there are two sets of TGTAAT inverted repeats in the 
cj0561c promoter region, which may contribute to the tight binding by CmeR. This 
possibility will be examined in future studies.  
  
    Bile salts are natural antimicrobials in animal intestines where C. jejuni establishes 
colonization. In other bacteria, it has been demonstrated that the expressions of numerous 
genes were up-regulated upon the exposure to bile salts (30). Previously it was shown that 
bile salts induce cmeABC expression (14). In this study, we also showed that both cj0035c 
and cj0561c were inducible by bile salts. Therefore, the up-regulation of cmeABC, cj0035c, 
cj0561c, and potentially other genes in vivo through CmeR induction may play a significant 
role in C. jejuni survival and adaptation in the host environment. It was identified in this 
study that other detergents, such as SDS, could also induce cj0035c and cj0561c (Fig. 3) as 
well as cmeABC (data not shown). Since detergents are ubiquitous in natural pollutants, the 
induction of CmeABC along with cj0035c and cj0561c by detergents may play a role in the 
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resistance to these toxic compounds and sustaining the viability of C. jejuni in the natural 
environments.   
 
    The mutants of cj0035c and cj0561c were tested on a variety of antibiotics, bile salts, 
detergent and toxic compounds. No significant MIC changes were observed with the cj0035c 
mutant or under inducing conditions. This result is in agreement with a previous report in 
which cj0035c was mutagenized and no change was observed in the MICs of four antibiotics 
(4). For the Cj0561c mutant, 2- to 4-fold decease in MICs of mercury and cadmium was 
observed. In addition, moderate MIC changes were detected when Cj0561c was induced by 
bile salts (Table 3). These results suggest that Cj0561c plays a measurable role in the 
resistance to antibiotics and toxic compounds when induced. Since CmeABC is a major 
efflux pump in C. jejuni, it was possible that the role of extrusion of antibiotics and toxic 
compounds mediated by cj0035c and cj0561c was masked by CmeABC. Therefore, double 
mutants of cj0035c/cmeB and cj0561c/cmeB were constructed to test this hypothesis. MIC 
tests on a variety of antibiotics, bile salts and other toxic compounds did not show any 
changes in the double mutants compared with isogenic cmeB mutant (data not shown). 
However, there is possibility that Cj0035c and Cj0561c may require the outer membrane 
channel protein CmeC for efflux activity. In AcrAB-TolC, a RND efflux pump in E. coli, the 
TolC serves as the outer membrane channel for AcrAB and is also shared by other efflux 
transporters (3, 11). In the double mutants, the CmeC was not active due to the polar the 
effect of the cmeB mutation on the expression of CmeC. Thus, restoration of CmeC in the 
mutant constructs may be needed to examine the functions of Cj0035c and Cj0561c. 
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    Cadmium and mercury are toxic to cellular physiological processes of both eukaryotic and 
prokaryotic cells. Detoxification of cadmium in bacterial cells is through efflux 
transportation and RND family efflux pumps have been reported to be responsible for the 
extrusion of cadmium (33). Steps in detoxification of mercury by bacterial cells are uptake, 
reduction and extrusion of mercury ion. The resistance to these heavy metals has been 
reported for both Gram-positive and Gram-negative bacteria and this phenotype plays a 
significant role in the survival and adaptation in the environments where heavy metals are 
encountered (33). Recently it was reported an RND family efflux pump, CznABC, was 
involved in the resistance to cadmium and zinc and was associated with the pathogenesis of 
Helicobacter pylori in a mouse model (35). The resistance to cadmium in C. jejuni may be an 
important phenotype both under in vitro and in vivo conditions. The association of cj0561c 
with the resistance to cadmium and mercury suggests that Cj0561c serves as an accessory 
protein in the periplasmic space for an efflux system. Since the overexpression of Cj0561c 
alone did not confer an additional advantage in the resistance to a various antimicrobials and 
toxic compunds, Cj0561c may require other membrane transporter proteins as functional 
partners, such as the CmeABC or other efflux transporters. This possibility will be examined 
in future studies and the identification of the functional partner(s) may lead to a better 
understanding of the role of Cj0561c in Campylobacter pathobiology. 
   
    In the chicken colonization study, the Cj0561c mutant was out-competed by the wild-type 
C. jejuni strain, although it colonized chickens as well as the wild-type strain when 
monoinoculated into chickens. This finding indicates Cj0561c is required for fitness of C. 
jejuni in vivo and facilitates the adaptation of C. jejuni in the intestinal tract. This finding is 
also consistent with the fact that the expression of Cj0561c is highly inducible by bile salts, 
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which are present in the intestinal tract. Thus, the modulated expression of Cj0561c and 
CmeABC by CmeR and bile salts may represent a newly discovered mechanism for 
Campylobacter adaptation to environmental changes.  
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TABLE 1. Plasmids and bacterial strains used in this study 
Plasmid and strains Relevant information Source 
Plasmid    
pGEM-T Suicide vector in C. jejuni; Ampr Promega 
pMW10 Shuttle vector for promoter fusion assay; Kanr (38) 
pQE30 Recombinant protein expression vector with N terminal 
his6-tag; Ampr  
Qiagen 
pRY108 E. coli – C. jejuni shuttle vector, Kanr (39) 
pRK2013 Helper plasmid hosted in DH5α used for triparental 
conjugation; IncP Kmr Tra RK2+ ΔrepRK2 repE1+ (18) 
DH5α E. coli host strain for promoter cloning and conjugation Invitrogen 
M15 E. coli host strain used to express recombinant protein Promega 
   
Campylobacter strains   
W7 A motile clone of NCTC11168 (ATCC 700819) ATCC 
W7B W7, cmeB::kan mutant This study 
W7R W7, cmeR::cat mutant This study 
W7-0561 W7, cj0561c::cat mutant This study 
W7-0035 W7, cj0035c::cat mutant This study 
W7-pMW0561 W7, cj0561c promoter-lacZ fusion on pMW10 This study 
W-pMW0035 W7, cj0035c promoter-lacZ fusion on pMW10  This study 
W7R-pMW561 W7R, cj0561c promoter-lacZ fusion on pMW10  This study 
W7R-pMW0035 W7R, cj0035c promoter-lacZ fusion on pMW10  This study 
W7B-561 W7, cmeB and cj0561c double mutant  This study 
W7B-0035 W7, cmeB and cj0035c double mutant  This study 
W7-pABC0561 W7, cmeABC promoter-cj0561c fusion on pRY108  This study 
W7B-pABC0561 W7B, cmeABC promoter-cj0561c fusion on pRY108  This study 
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TABLE 2. PCR Primers used in this study 
Primers for Sequences*   Amplified target 
Promoter fusion  
0035PF ACGGATCCTATAAAGCAGTGCTGATATCG (BamHI) 
0035PR ACTCTAGAAAACTTTGTTCTACATGAGAA (XbaI) 
cj0035c promoter 
561PF ACGGATCCATAGCTCGTTCTAAATCCAAGT (BamHI) 
561PR ACTCTAGACCACACCTATGCTTAAATTTCC (XbaI) 
cj0561c promoter 
  
EMSA  
cj0035uF1 TTTAGCAAAGCCGTGAATTTTGGTG  
cj0035uR1 GTTCATTTTGGTTTAAATTTTGCAT 
cj0035c promoter 
cj0561uF1 TGATTGGGTTAAAATGGA 
cj0561uR1 TTCTAAAAATTCTATCTAAAAAAAC 
cj0561c promoter 
   
Mutagenesis   
cj0035cFU ACGGATCCCACAAAACAAACTCGAAACGAT (BamHI) 
cj0035cFL AAGCCTCTTCTTTGGCTTGAA 
cj0035cRU TGTTGCTAATGCTAAATTGTCCTT 
cj0035cRL TATCTAGAGCTTGGTTTCATCGCACC (XbaI) 
cj0035c  
561UF TGAAAGTGCGATAATAGGCATA 
561UR  AAGGATCCGCACCCACACCTATGCTTAAAT (bamHI) 
561LF AGTCTAGAATATGAAGCAGTAGGAACTGAT (XbaI) 
561LR  TGTTTAAATGTTAGCGATGAGA 
cj0561c  
chlU ACGGATCCAAAGAGTGACCGCCGAGA  (BamHI) 
chlL ACTCTAGACAGTGCGACAAACTGGGA (XbaI) 
cat cassette 
  
Recombinant protein  
561clF  AGGGATCCGTAGAATTTCAAGAAGGTTTTA (BamHI) 
561clR ATCCCCGGGTTAGAATTTATATCCTATACCA (SmaI) 
cj0561c  
  
Protein overexpression  
0561Fc AATCTAGAAACAACAAACATTTCAAGGAGAACAT (XbaI) 
561Rc AAAGAGCTCATAAGGCAAGCTTTTCTTTGGTTTT (SacI) 
cj0561c  
BSF1 AAAAGGATCCTAAATGGAATCAATAGCTCC (BamHI) 
AR2 ATCTCGGTATGATCTAGATCA (XbaI) 
cmeABC promoter 
(1) 
* The restriction site in each primer is underlined and indicated in the parenthesis. 
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TABLE 3. MICs of various antibiotics in various Campylobacter strains in the 
presence of cholic acid (2.0 mg/ml) 
MIC (μg/ml) 
Antibiotics W7 W7-0561 W7-0035 
Ciprofloxacin 0.125 0.25 (-)* 0.125  (-) 
Erythromycin 0.25 0.125 (2) 0.25  (-) 
Tetracycline 0.0625 0.031 (2) 0.0625  (-) 
Rifampin 256 128 (2) 256  (-) 
Polymyxin B 8 8 (2) 8  (-) 
Cefotaxime 8 8 (2) 8  (-) 
SDS 512 128 (4) 512  (-) 
Ethidium bromide 0.5 1 (2) 0.5  (-) 
* Numbers in brackets indicate the fold changes in MIC compared with W7. 
 
 
 
 
 
 
 
TABLE 4. MIC results of mercury and cadmium 
W7 W7-0035 W7-0561 W7-pABC-0561 
  MIC (μg/ml) 
HgCl2 32 32 (-)* 16 (2) 32 (-) 
CdCl2 8 8 (-) 2 (4) 8 (-) 
* Numbers in brackets indicate fold changes in MIC compared with W7 
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FIG. 1. Transcriptional analysis of cj0035c (A) and cj0561c (B) in C. jejuni W7 and 
its isogenic CmeR mutant (W7R) using promoter fusion assay. Data represent the 
mean ± standard deviation of triplicate samples. 
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FIG. 2. Electrophoretic Mobility Shift Assay shows the binding of CmeR to DIG-
labeled cj0035c (A) and cj0561c (B) promoter DNA, but not to DIG-labeled cmeA 
interal DNA (C). Arrows indicate the DNA-CmeR complex. The numbers on top of 
each panel indicate the amounts of CmeR (ng) used in each binding reactions. 
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FIG. 3. Induction of cj0035c (panel A) and cj0561c (panel B) in wild-type W7 by 
cholic acid (2.0 mg/ml), taurocholic acid (4.0 mg/ml), and SDS (25 ug/ml). Data 
represent the mean ± standard deviation of triplicate samples. 
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FIG. 4 Western blotting analysis of Cj0561c in the membrane (Lane 2), periplasmic 
(Lanel 3) and spheroplastic (Lanel 4) fractions of W7-pRYabc561. Cj0561c was 
visualized only in the membrane fraction as indicated by the arrow. Lane 1 is the 
prestained protein ladders with the 25 and 37 Kd bands labeled.  
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FIG. 5. Western blotting analysis of the expression of Cj0561c in C. jejuni W7-pABC-0561 
(Lane 1), W7-561 (Lane 2), and W7 (Lane 3). Lane 4 contains the prestained protein ladders.  
Arrow indicates the Cj0561c bands.  
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FIG. 6.  Colonization of C. jejuni W7 and its isogenic cj0035c and cj0561c mutants in chickens. 
Panel A shows the colonization in the groups mono-inoculated with W7, W7-0035 and W7-
0561. Panel B shows the results of a mixed infection with W7 and W7-0561. Bar indicated 
means. * indicates significant differences compared with wild-type group (p<0.001). 
 122
 
CHAPTER 5. REGULATION OF DCUA AND DCUB AND THEIR ROLES IN 
CAMPYLOBACTER JEJUNI COLONIZATION IN CHICKEN CECA 
 
A paper to be submitted to the Journal of Bacteriology 
 
B. Guo, D. L. Reynolds, and Q. Zhang 
Department of Veterinary Microbiology and Preventive Medicine, the Iowa State University, 
Ames, IA 50010. 
 
Abstract 
 
    Campylobacter jejuni NCTC 11168 has two putative C4-dicarboxylate transporters, DcuA 
and DcuB, which are potentially involved in Campylobacter adaptation to oxygen-limited 
conditions in the intestinal tract. In a recent study by our laboratory on the transcriptional 
regulator CmeR, we found that the expressions of the putative C4-dicarboxylates transporters 
DcuA and DcuB were upregulated in the CmeR mutant. In this study, the function and 
regulation of DcuA and DcuB were elucidated by mutagenesis and transcriptional lacZ 
fusion experiments as well as animal studies. It was demonstrated that both DcuA and DcuB 
were involved in C. jejuni NCTC 11168 growth under oxygen limited conditions. Mutation 
in CmeR increases the expressions of both dcuA and dcuB although both genes are 
constitutively expressed with DcuA at a higher level than DcuB under microaerobic 
conditions.  Both DcuA and DcuB were inducible by fumarate and oxygen-limited 
conditions. Chicken colonization studies indicated that at least one of the two genes is needed 
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for maximal colonization in chicken ceca by C. jejuni. Null mutations of both genes 
significantly reduced the ability of C. jejuni to colonize in the chicken ceca (p<0.001). It was 
concluded that anaerobic C4-dicarboxylate transporters DcuA and DcuB in C. jejuni were 
regulated by CmeR and are required for Campylobacter adaptation to the intestinal tract. 
 
  
Introduction 
 
    Campylobacter jejuni has become one of the major foodborne pathogens worldwide and 
causes diarrhea, abdominal pain, colitis and other clinical diseases in humans (3, 23). The 
consumption of undercooked poultry meat, unpasteurized milk and unchlorinated surface 
water contaminated by C. jejuni, mishandling of contaminated animal meat products, or close 
contact with Campylobacter infected animals are the major risk factors for contracting C. 
jejuni infections in humans (20, 30). C. jejuni is ubiquitous in the nature and has been 
isolated from domestic and wild animals as well as birds (1, 4, 11). Poultry and other farm 
animals, especially broilers and turkeys, are often colonized in the gut by C. jejuni without 
causing clinical diseases and these animals are the major reservoir of C. jejuni (5, 17, 20, 24, 
33).  
 
    The intestinal tract of chickens is generally considered to be an environment with limited 
levels of oxygen. The mechanisms of C. jejuni survival and adaptation in such an 
environment is not well understood. However, genome sequence information of C. jejuni 
indicates that the bacterium has unique physiological and metabolic characteristics (7, 19). 
Although Campylobacter is not an anaerobe, the genes encoding enzymes responsible for 
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anaerobic respiration and alternative electron transport, such as fumarate reductase and 
aspartase, are present in the C. jejuni 11168 genome (19). It has been shown experimentally 
that Campylobacter is capable of anaerobic respiration through alternative electron acceptors, 
such as fumarate and nitrate (21, 22). Among the other genes identified in C. jejuni genome 
are the C4-dicarboxylate transporters, DcuA and DcuB, which are members of the Dcu 
(dicarboxylate uptake) family of C4-dicarboxylate transporters responsible for the uptake and 
efflux of C4-dicarboxylate in the process of fumarate respiration when the oxygen level is 
low or not available (13). DcuA and DcuB have been characterized in E. coli, Wolinella 
succinogenes and other bacterial species and are involved in anaerobic respiration (6, 15, 25, 
32).  The C4-dicarboxylate transporters in E. coli are regulated by a two-component sensing 
and response system and a global regulator, FNR (9). In C. jejuni, it has been demonstrated 
that dcuA and dcuB were up-regulated in chicken ceca and in vitro cultures under oxygen-
limited conditions (28). Recently it was demonstrated by microarray and real-time RT-PCR 
in our laboratory that dcuA and dcuB are subject to the regulation of CmeR, a pleiotropic 
transcriptional factor modulating the expression of multiple genes of diverse functions (26). 
But it is unknown if CmeR directly or indirectly regulates dcuA and dcuB, and the functions 
of dcuA and dcuB in the anaerobic respiration and in vivo colonization are unclear. The goal 
of this study was to further determine the regulation of dcuA and dcuB by CmeR and the 
contribution of DcuA and DcuB to anaerobic respiration and intestinal colonization. 
Understanding the basic mechanisms of Campylobacter adaptation in the intestinal tract will 
facilitate the design of strategies to control the colonization of Campylobacter in animal 
reservoir and ultimately improve the microbial safety of food supplies. 
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Materials and Methods 
 
    Bacterial strains and growth conditions. Bacterial strains used in this study are listed in 
Table 1. C. jejuni strains were maintained and grown in Mueller Hinton (MH) broth at 42 °C 
in a sealed jar filled with a gas mixture of 5% O2, 10% CO2 and 85% N2. For cultures under 
oxygen limited conditions, C. jejuni were grown in a sealed jar filled with the microaerobic 
gas mixture described above and an additional CampyGene GasPak (Oxoid) to reduce the 
oxygen level.  E. coli strains were maintained and grown in LB medium for 16 ~ 24 hr on a 
shaker at 200 rpm. For the selection of E. coli transformants, antibiotics were added to the  
medium at concentration of 100 μg/ml (ampicillin), 30 μg/ml (kanamycin), and 20 μg/ml 
(chloramphenicol). For the selection of dcuA and dcuB single and double mutants, culture 
media were supplemented with 20 μg/ml of kanamycin and/or 4 μg/ml chloramphenicol as 
needed. 
 
    PCR and RT-PCR. PCR was routinely performed in a 50 μl reaction volume containing 5 
μl of 10× reaction buffer, 200mM dNTPs, 10 pmol/μl of each primers, 50 ~ 100 ng DNA 
template and 2.5 units of the Taq DNA polymease (Promega) and the cycling conditions 
were 94 °C 4 min, 30 ~ 35 cycles of denaturing  (30 s at 94 °C), annealing (30 s at 
temperature of 5 °C below the calculated melting temperature),  and extension for 1 min per 
kb at 72 °C. High-fidelity DNA polymerase including Ex Taq (Takara) and Pfu (Strategene) 
were used to amplify the promoter DNA for gel-shift assay and transcriptional fusion. 
 
    Mutagenesis of dcuA and dcuB.  dcuA and dcuB were inactivated through insertional 
mutagenesis by either a kanamycin or chloramphenicol resistance cassette through 
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homologous recombination as described in a previous study (2). Internal fragments of dcuA 
and dcuB were amplified (with the Taq polymerase, Promega) from C. jejuni W7 genomic 
DNA with primer pairs dcuA-F/dcuA-R, and dcuB-F/dcuB-R, respectively (Table 2). The 
PCR products were purified by a PCR Purification Kit (Qiagen), and the DNA was inserted 
into pGEM-T vector (amp+) through A-T cloning. The pGEM-T carrying the dcuA and dcuB 
fragments were transformed into E. coli JM109 competent cells (Promega) and selected on 
ampicillin-containing LB plates. The E. coli containing the cloned dcuA or dcuB was 
propagated for plasmid preparation. The pGEM-T plasmids carrying dcuA and dcuB, 
respectively, were used as templates in inverse PCR with primer pairs dcuA-inF/dcuA-inR, 
and dcuB-inF/dcuB-inR, respectively, as listed in Table 2 by using the Pfu Turbo polymerase 
(Stratagene).  Chloramphenicol and kanamycin resistance cassettes originally from C. coli 
were amplified from pUOA18 and pMW10, respectively, with primer pairs chlU/chlR, and 
kanU/kanL, respectively (Table 2). The inverse PCR products and amplified antibiotic 
cassette DNA were purified by using a PCR Kit (Qiagen) and blunt-end ligations were 
performed by T4 DNA ligase, leading to the ligation of pGEM-T carrying dcuA or dcuB with 
the cat or kan cassette, respectively.  The ligated products were transformed to JM109 
competent cells and transformants with pGEM-T carrying cat flanked by the dcuA fragments 
and pGEM-T carrying kan flanked by the dcuB fragments were selected on LB plates 
supplemented with correspondent antibiotics. Single colonies were subcultured and 
confirmed by PCR, showing the correct insertion of cat and kan into dcuA and dcuB, 
respectively. The plasmid constructs were used as suicide vectors and were electroporated 
into C. jejuni W7 competent cells. The C. jejuni transformants were selected on MH plates 
supplemented with chloramphenicol or kanamycin and confirmed by PCR. 
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    To make a dcuA and dcuB double mutant, the genomic DNA of the dcuA mutant with the 
cat cassette insertion was introduced into the dcuB::kan mutant through natural 
transformation.  The double mutant was selected on MH plates supplemented with 
chloramphenicol and kanamycin and both dcuA and dcuB insertional mutations were 
confirmed by PCR. 
 
    Construction of dcuA and dcuB promoter-lacZ transcriptional fusions. The DNA 
covering the putative promoter regions of dcuA and dcuB were amplified from C. jejuni 
11168 by the Pfu Turbo polymerase with primers dcuA-PF and dcuA-PR, dcuB-PF and 
dcuB-PR, and aspA-PF and aspA-PR, respectively (Table 2). The PCR amplified DNA 
fragments were digested by BamHI and XbaI and cloned into pMW10 linearized with the 
same restriction enzymes, resulting in pMW10-dcuA, pMW10-dcuB, and pMW10-aspA, on 
which the dcuA, dcuB and aspA promoter DNA was fused with the promoterless LacZ 
reporter gene. The constructed plasmids were transformed into E. coli DH5α and the inserted 
promoter sequences of dcuA, dcuB and aspA were confirmed by DNA sequencing. Then 
pMW10-dcuA, pMW10-dcuB and pMW10-aspA in DH5α were transferred to C. jejuni W7 
and its CmeR mutant by triparental conjugation (16).  
 
    ß-galactosidase assay and induction of aspA-dcuA and dcuB. To measure the promoter 
activity of dcuA, dcuB and aspA-dcuA, C. jejuni W7 and its isogenic CmeR mutant carrying 
the dcuA, dcuB and aspA-dcuA promoter fusion constructs were grown in MH medium under 
the microaerobic condition (16 to 24 hr) at 42°C.  One hundred microliter of the cultures 
were taken and ß-galactosisase activities were analyzed and recoded as miller units as 
described previously (14).  
 128
 
    C. jejuni W7 and the isogenic cmeR mutant carrying aspA-dcuA and dcuB promoter fusion 
constructs were grown under the microaerobic and oxygen limited conditions in MH and MH 
supplemented with 20 mM sodium fumarate (16 to 24 hr) at 42°C to determine the induction 
activity on aspA-dcuA and dcuB promoters by low oxygen levels and fumarate.  ß-
galactosidase assays were conducted as described above.  
 
     Chicken colonization study. Sixty one-day old broiler chickens were purchased from a 
commercial hatchery and housed in the Iowa State University Laboratory Animal Resources 
(LAR) facilities according to institutional animal CPN guidelines. The birds were divided 
into four groups and each group was orally inoculated at three days of age with 
approximately 105 CFU/bird of C. jejuni W7, single mutants of dcuA and dcuB, or the 
dcuA/dcuB double mutant. The inoculated birds were provided with non-medicated feed and 
water ad libitum. After 5 and 10 days post inoculation (dpi), 10 birds from each group were 
euthanized by CO2 and cecal contents were collected in test tubes on ice. Cecal contents were 
weighed and diluted in 1:10 with MH broth added with the selective and growth supplements 
purchased from Oxoid. Diluted cecal samples were plated on MH agar plates supplemented 
with the Campylobacter growth and selective agents purchased from Oxoid. Campylobacter 
colonies on each plate were counted and colony forming units (CFUs) per gram of cecal 
sample were calculated. Campylobacter colonies recovered from the groups inoculated with 
the mutant strains were restreaked on MH plates supplemented with chloramphenicol (for 
dcuA mutant), kanamycin (for dcuB mutant), or both (for dcuA/dcuB double mutant) to 
confirm their identity. The CFUs/gram of fecal sample of each group was used for statistical 
analysis with ANOVA.  
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Results 
 
    Sequence features of DcuA and DcuB in C.  jejuni. DucA and DcuB are putative C4-
dicarboxylate transporters based on the sequence annotation of C. jejuni 11168 (19). DcuA 
(445 amino acids) is encoded by cj0088 and DcuB (474 amino acids) is encoded by cj0671.  
BLAST search indicated that DcuA and DcuB of C. jejuni resemble each other and share 
36% sequence identity, which is consistent with findings in other bacterial species that DcuA 
and DcuB are related (13). BLAST search also showed that the DcuA in C. jejuni and the 
DcuA in Campylobacter coli, Campylobacter upsaliensis, Campylobacter lari and 
Campylobacter fetus have sequence identities of 97%, 88%, 90%, and 67%, respectively. 
DcuB in C. jejuni and its homologous DcuB in C. coli, C. upsaliensis, C. lari, and C. fetus 
have sequence identities of 94%, 95%, 79% and 68% respectively.  Sequence alignment also 
showed that the DcuA and DcuB in C. jejuni are 53% and 69% identical in amino acids to 
the DcuA and DcuB of E. coli, respectively. Transmembrane helix predictions using 
TMHMM Server v. 2.0 (http://www.cbs.dtu.dk/services/TMHMM/) indicated that both 
DcuA and DcuB had 12 transmembrane fragments. BLAST search 
(http://www.ncbi.nlm.nih.gov/blast/) also identified that DcuA and DcuB in C. jejuni contain 
the conserved domains of anaerobic C4-dicarboxylate membrane transporters 
(pfam03605.10). Promoter prediction indicated that dcuA shares a common RpoD-dependent 
promoter with its upstream gene aspA (encoding aspartase), potentially forming a two-gene 
operon. No predicted promoter exists in the immediate upstream region of dcuB, which 
transcribed divergently from the flanking genes. 
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    Growth characteristics of dcuA and dcuB single and double mutants under 
microaerobic and oxygen limited conditions. C. jejuni W7 and its isogenic single and 
double mutants of dcuA and dcuB were compared for growth in MH medium with or without 
sodium fumarate under microaerobic and oxygen limited conditions and the optical densities 
at 600 nm (OD600) of the bacterial cultures were measured at 24 and 48 hr after inoculation 
(Fig. 1). Under microaerobic conditions in the MH medium, although single and double 
mutants of dcuA and dcuB showed reduced growth for the 24 hr cultures, there was no 
significant difference among the wild type and mutant strains in bacterial yield in the 48 hr 
cultures. This is an indication that single and double mutations of dcuA and dcuB do not 
affect the growth rates in vitro under microaerobic conditions. As shown in Fig. 1, when 
sodium fumarate was added to MH medium at a concentration of 20 mM, a significant 
difference was observed in the 48 hr cultures between wild type strain and the double mutant 
of dcuA and dcuB (p<0.001), indicating that  DcuA and DcuB are involved in the utilization 
of sodium fumarate in C. jejuni. When grown under oxygen limited conditions in the MH 
medium, the double mutant of dcuA and dcuB showed consistent poor growth, in comparison 
with the wild-type strain (p<0.001), regardless of the time points and the presence of sodium 
fumarate in the media (Fig. 1). The single mutants of dcuA and dcuB also showed significant 
decrease in growth in MH or MH supplemented with sodium fumarate when measured at 48 
hr (p<0.001). These results indicate that DcuA and DcuB contribute to Campylobacter 
growth under oxygen-limited conditions. 
 
    CmeR regulates dcuA-aspA and dcuB. C. jejuni W7 and its isogenic CmeR mutant 
transformed with the promoter fusion plasmids pMW-dcuA, pMW-dcuB and pMW-aspA-
dcuA were grown in MH broth overnight and used for β-galactosidase assays. β-
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galactosidase activities indicated that there was no detectable promoter activity in the DNA 
sequence immediately upstream of dcuA. A RT-PCR was performed with primer aspA-F and 
dcuA-PR spanning the junction of aspA and dcuA (1470 bp) and it was demonstrated that 
aspA and dcuA were co-transcribed (Fig. 2). Fig. 3 shows the results of ß-galactosidase 
activities from the aspA-dcuA and dcuB promoter fusion assays in wild-type W7 and the 
CmeR mutant. Strong activities were detected with the promoter in front of aspA-dcuA and 
there was an approximately 1.9-fold increase in the promoter activity in the CmeR mutant 
compared with the wild-type. It was also demonstrated that dcuB was expressed in the wild-
type background, but at a much lower level compared with aspA-dcuA. The promoter activity 
of dcuB was increased by 1.4-fold in the CmeR mutant compared with the wild-type. The 
elevated expressions of aspA-dcuA and dcuB in the CmeR mutant background are consistent 
with our previous findings from the microarray and real-time PCR assays.  
 
    dcuA and dcuB are inducible under oxgen-limited conditions and by C4-
dicarboxylates. C. jejuni W7 carrying the aspA-dcuA and dcuB promoter constructs were 
grown under different conditions and β-galactosidase assays were performed. As shown in 
Fig. 4, both sodium fumarate and low oxygen levels increased the expression of aspA-dcuA 
and dcuB. The promoter activity of aspA-dcuA was elevated by approximately 1.2-fold in the 
presence of 20 mM sodium fumarate, but no change was observed under O2 limited 
conditions. In the presence of 20 mM sodium fumarate and under oxygen limited conditions, 
the promoter activity of aspA-dcuA did not show further increase compared with that in the 
presence of sodium fumarate only. The dcuB promoter activity was increased by 1.4- and 
1.5-fold, respectively, in the presence of 20mM sodium fumarate and under O2 limited 
conditions; and dcuB promoter activity was elevated further by up to 1.7-fold both in the 
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presence of sodium fumarate and under oxygen limited conditions. The relatively higher 
levels of induction on dcuB promoter activity in the presence of sodium fumarate and oxygen 
limited conditions may be due to its low promoter activity compared with that of aspA-dcuA 
promoter.  
 
    dcuA and dcuB genes are involved in in vivo colonization of C.  jejuni in chickens.  
Chickens were inoculated with C. jejuni W7 and isogenic dcuA and dcuB single and double 
mutants to evaluate the roles of dcuA and dcuB in intestinal colonization of the host. Three-
day old chickens were inoculated orally with 105 CFU per birds of C. jejuni W7 and dcuA 
and dcuB single and double mutants and sampled on days 5 and 10 post inoculation. As 
shown in Fig. 5, there was a significant decrease in the colonization of dcuA/dcuB double 
mutant in ceca compared with C. jejuni W7 (p<0.001). There was no difference observed 
between C. jejuni W7 and the dcuA or dcuB single mutants in the colonization in chicken 
ceca, suggesting that at least one of the two transporters is needed for optimal colonization of 
C. jejuni in chicken ceca. 
 
Discussion 
 
    In this study, we demonstrated that C4-dicarboxylate transporters DcuA and DcuB were 
involved in Campylobacter growth under oxygen limited condition and the expression of 
dcuA and dcuB was regulated by CmeR. This conclusion is supported by the following 
observations. Under microaerobic conditions, the overall growth of C. jejuni in MH medium 
was not affected by the single or double mutations of dcuA and dcuB, but under oxygen 
limited conditions or when sodium fumarate was added to the MH medium, the growth of the 
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double mutant of dcuA and dcuB was reduced significantly (Fig. 1). Furthermore, RT-PCR 
assay revealed that aspA and dcuA are co-transcribed and share a common promoter. 
Promoter fusion assays showed that dcuA and dcuB were down-regulated by CmeR and 
inducible by low levels of oxygen and sodium fumarate. The double mutations of dcuA and 
dcuB significantly reduced the colonization of C. jejuni in chicken ceca (p<0.001). 
 
    Fumarate respiration is a metabolic process in facultative and strictly anaerobic bacteria in 
which fumarate is utilized as an alternative electron acceptor when oxygen is unavailable 
and,  in the process of electron transfer, fumarate is reduced to succinate (22, 31). C4-
dicarboxylate transporters are needed for the uptake and efflux, or exchange of fumarate and 
other C4-dicarboxylate sugars or amino acids, such as malate and aspartate, which can be 
converted to fumarate (12, 13). DcuA and DcuB are C4-dicarboxylate transporters initially 
identified in E. coli, play an important role for bacterial growth under anaerobic conditions 
(10). Recently dcuA and dcuB have been characterized in Wolinella succinogenes of ε-
proteobacteria, which is a species closely related to Campylobacter and the DcuA and DcuB 
in this bacterium can complement the function of one another (25). But double mutation 
impaired the ability of Wollinela to grow in minimal medium with fumarate under anaerobic 
condition (25). In our study, it was demonstrated that growth of DcuA and DcuB single and 
double mutants in vitro were reduced compared with the wild-type strain, especially under 
oxygen limited conditions with sodium fumarate supplemented in the medium. Our results on 
DcuA and DcuB in C. jejuni are in agreement with the findings reported previously in E. coli 
and Wolinella.    
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    The regulation of DcuA and DcuB in E. coli has been well characterized in that DcuA is 
constitutively expressed and DcuB is expressed at very low level under aerobic conditions 
but inducible by low oxygen levels and C4-dicarboxylate substrates (9, 31). In this study, 
DcuA and DcuB were both expressed constitutively under microaerobic conditions, but the 
expression of DcuA was much higher that that of DcuB. Since C. jejuni is a microaerophilic 
bacterium, the microaerobic conditions may be a factor that triggers the constitutive 
expression of both the DcuA and DcuB. Promoter fusion assays indicated that the DcuA and 
DcuB genes were elevated by both low oxygen levels and the presence of sodium fumarate. 
However, the levels change were not as high as shown in a previous study with E. coli (9, 
31). This may be because either the two genes are already expressed at a relative high level 
under microaerobic condition, or the oxygen levels under the oxygen limited conditions were 
not low enough to further increase the expression of DcuA and DcuB. The higher induction 
of DcuB compared with DcuA observed in this study is in agreement with the finding in E. 
coli (9). Promoter fusion assays in the CmeR mutant background further confirmed the 
findings from microarray and quantitative real-time PCR analysis (26).  
 
    One of the major factors that effect the ability of enteric bacteria, such as E. coli, 
Salmonella, Helicobacter and Campylobacter to colonize and persist in the host intestinal 
tract is presumably the anaerobic respiration mechanisms of these bacteria. Studies on 
fumarate reductase in some species have demonstrated the importance of anaerobic 
mechanisms in bacterial in vivo colonization. For example, the fumB mutant of Helicobacter 
pylori has an impaired ability in colonizing the mouse host (8). In C. jejuni, it has been 
experimentally demonstrated that the activities of fumarate reductase are increased under low 
oxygen level (22) and the bacterium can perform anaerobic respiration by utilizing 
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alternative electron acceptors under these conditions (21). In this study, double mutations of 
DcuA and DcuB in C. jejuni caused a significant reduction in cecal colonization of chickens, 
but a single mutation in either DcuA or DcuB did not affect the ability of C. jejuni to 
colonize chickens. The in vivo findings indicate that DcuA and DcuB collectively are 
important for Campylobacter adaptation in the intestinal tract. It also suggests that DcuA and 
DcuB compensate each other in their function in C. jejuni. This colonization is in agreement 
with a previous study on the growth-no-suppression (GNS) phenotype of Salmonella 
typhimurium in which neither the DcuA mutant nor the DcuB mutant of Salmonella 
typhimurium lost the ability to outcompete the indictor strain in the chicken intestinal 
colonization model (18).  
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TABLE 1. Bacterial plasmids and strains used in this study 
Plasmids or strains Description or phenotype 
Source or 
reference 
Plamids     
pGEM-T A-T cloning vector Promega 
pMW10 Promoter fusion, shuttle vector, Kanr (29) 
pUOA18 source of cat cassette (27) 
pMW10-dcuA pMW10 with dcuA promoter-LacZ fusion This study 
pMW10-dcuB pMW10 with dcuB promoter-LacZ fusion This study 
pMW10-aspA/dcuA pMW10 with aspA/dcuA promoter-LacZ fusion This study 
   
C. jejuni    
W7 NCTC 11168, motile clone ATCC 
W7R C. jejuni W7, cmeR::cat.  This study 
W7-A C. jejuni W7, dcuA::cat. This study 
W7-B C. jejuni W7, dcuB::kan.  This study 
W7-AB  C. jejuni W7, dcuA::cat/dcuB::kan. This study 
   
 E. coli   
JM109 Cloning host for mutagenesis of dcuA and dcuB Promega 
DH5α Cloning host for promoter fusion Invitrogen 
DH5α, pRK2013 Conjugation helper strain (16) 
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TABLE 2.  Oligo nucleotide PCR primers used in the study 
 
Oligo names Sequence* (5'-3') 
chlU ACGGATCCAAAGAGTGACCGCCGAGA  (BamHI) 
chlL ACTCTAGACAGTGCGACAAACTGGGA (XbaI) 
kanU ATGGATCCTGCAAGGAACAGTGAAT (BamHI) 
kanL ATTCTAGAGCGATGAAGTGCGTAAG (XbaI) 
dcuA-F GATATAATGATAATTTTGCAAGTAATCG 
dcuA-R AATAAGCATAGGAGCTAATACA 
dcuA-inF CTTTATGCAACCGCAATTTCAAGT 
dcuA-inR CTATAAAAGCTGCAAGCATACAAGCTACAA 
dcuB-F TGGACTTTTTAACAAGCCTTAGTGAG 
dcuB-R AAAGATAACCTGCTGCCATAGCAA 
dcuB-inF CAAGTTGTAAAAAATGGCATTCCTCA 
dcuB-inR ACCAAGAAAAAATTCCTATACACAATACAC 
dcuA-PF   TCTATAATTCAGTAGGTATAGTAACAGCTT 
dcuA-PR  AATCTAGAATACCGATAAAAATCGCCCCA (XbaI) 
dcuB-PF  AAGAATTTAAAGTCGATATAGGGCGAA 
dcuB-PR AATCTAGAATTTGGATTGCAAATTGCCCTG (XbaI) 
aspA-PF  CATTTATTTTAATCTTATCTATGTTTATTGTAATTTCTTCC 
aspA-PR AATCTAGAATTTTCAACAGCTCTAAAAGTTTGCAC (XbaI) 
aspA-F ATGATTTTATTGGGGAATTGGAAATCT 
dcuBPF2 TCGATATAGGGCGAAGAACTATT 
dcuBPR2 AATCTAGACTGCCTCACTAAGGCTTGT 
* Restriction sites are underlined and labeled in parenthesis 
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FIG. 1. Growth of C. jejuni W7 (●), W7-A (○), W7-B (▲) and W7-AB (□) under 
microaerobic (Panels A, B) and oxygen limited anels C, D) conditions in MH medium 
anels A, C) or MH medium supplemented with sodium fumarate (Panels B, D). Each 
ta point represents the mean OD600 ± standard deviation of three replicates in one 
periment.  
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FIG. 2. Genomic organization of the dcu genes (A) and co-transcription of aspA and dcuA 
as determined by RT-PCR (B). In panel B, Lane 1 contains DNA ladder with the sizes 
labeled on the left; Lane 2 is the RT-PCR reaction with aspA-dcuA specific primers and 
total bacterial RNA; and Lane 3 is a control PCR reaction in which the RT step was omitted. 
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FIG. 3. Transcriptional fusion assays of aspA-dcuA and dcuB promoters in C. jejuni W7 and 
its isogenic CmeR mutant (W7R). Each bar represents the mean Miller units ± standard 
deviation of three replicates in one experiment with mean value labeles. * indicates significant 
differences in aspA-dcuA and dcuB promoter activities under wild-type and CmeR mutant 
background (p<0.001). 
 145
1249.3
1411.2
1372.7
1161.0
0.0
200.0
400.0
600.0
800.0
1000.0
1200.0
1400.0
1600.0
1800.0
MH, microaerobic MH+SF,
microaerobic
MH, oxygen
limited 
MH+SF, oxygen
limited 
M
ill
er
 U
ni
ts
(A) 
(B) 
 **
 
 
 
 
 
 
 
 
258.6
374.1
396.1
459.0
0.0
100.0
200.0
300.0
400.0
500.0
600.0
MH, microaerobic MH+SF,
microaerobic
MH, oxygen
limited 
MH+SF, oxygen
limited 
M
ill
er
 U
ni
ts
 
* 
*
* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 4. Induction of aspA-dcuA (Panel A) and dcuB (Panel B) promoters in C. jejuni W7 in MH 
under microaerobic and oxygen limited conditions with or without sodium fumarate (SF) added 
Each bar represents the mean Miller units ± standard deviation of three replicates in one 
experiment with mean value labeled.  
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FIG. 5.  Levels of colonization of various C. jejuni constructs including W7, W7-A, W7-B 
and W7-AB in chickens. Groups are labeled on the X axis. The Y axis represents the log 
values of the CFU per gram cecal contents. Samples were collected on DPI 5 (Panel A) and 
DPI 10 (Panel B). * indicates significant difference in cecal colonization between the double 
mutant and the wild-type strain (p<0.001). 
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CHAPTER 6. GENERAL CONCLUSIONS 
 
    In this project, it was demonstrated that the multidrug efflux pump CmeABC is present in 
various Campylobacter spp. including C. jejuni, C. coli, C. upsalienesis, C. lari and C. fetus. 
The genetic organizations and predicted structures of CmeABC are highly conserved in 
different Campylobacter spp. It was also shown that CmeABC in different Campylobacter 
spp. is a key player in the intrinsic resistance to multiple antimicrobials, detergents, and other 
toxic compounds. The conserved nature of CmeABC in genetics, structure, and function 
suggest that this efflux system is evolutionally important for Campylobacter adaptation to 
environments. The revealed intrinsic resistance profiles of various Campylobacter spp. will 
also facilitate the optimization of culture media for the isolation of Campylobacter from 
clinical samples.  Based on the results from multiple molecular studies, we conclude that 
CmeR, a transcriptional repressor for CmeABC, also regulates other membrane transporters, 
including Cj0035c, Cj0561c, and the C4-dicarboxylate transporters DcuA and DcuB. CmeR 
directly regulates Cj0035c and Cj0561c by binding to the promoter regions of the two genes 
and represses their transcription. However, it is unknown at present if CmeR directly or 
indirectly regulates DcuA and DcuB. Cj0561c likely encodes a periplasmic fusion protein 
physically associated with the membrane and likely functions as a partner with an inner 
membrane transporter in conferring antibiotic resistance. A clear role of Cj0035c in antibiotic 
resistance was not detected using the conditions employed in this study. Our work also 
showed that Cj0561c is highly induced by bile salts and is likely upregulated in the intestinal 
tract of animals. This finding is consistent with the result of the in vivo colonization study, in 
which the Cj0561c mutant showed a reduced fitness in the gut. Together, these results 
suggest that the regulated expression of Cj0561c contributes to Campylobacter adaptation in 
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vivo.  An additional contribution of this project is the confirmed regulation of DcuA and 
DcuB by CmeR and the establishment of the Dcu transporters as key players in facilitating 
Campylobacter adaptation to oxygen-limited conditions in vitro and in vivo. The interplay 
between the drug efflux system and other physiological processes suggests that the efflux 
machinery in Campylobacter is not only for antimicrobial resistance, but may also have 
natural functions that remain to be uncovered in futures studies. Together, findings from this 
project have significantly improved our understanding of the efflux transporters in 
Campylobacter. Targeting the efflux transporters may not only control antibiotic resistance, 
but also potentially prevent Campylobacter colonization in the intestinal tract. 
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